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SUMMARY OF CONTENT 
 
 
This MPH dissertation undertakes a systematic review on factors associated with patient and health 
system delay in diagnosing and commencing treatment for pulmonary tuberculosis in Middle East and 
North Africa (MENA). The dissertation is composed of three main parts: namely parts A, B and C.  
 
Part A is the research protocol, which give brief background to research topic and the process of this 
review. This systematic review aims to assess factors associated with patient and health system delay 
for diagnosis and initiation of treatment of pulmonary tuberculosis in Middle East and North Africa 
(MENA). 
 
Part B elaborates on the background and highlights the importance of this research by examining the 
existing theoretical and empirical literature relevant to the topic.  
 
Part C presents the entire research project in a format suitable for PLOS journal submission. The 
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PART A: PROTOCOL 
 





LIST OF ABBREVIATIONS 
 
AFB             Acid Fast Bacilli 
DOTS          Directly Observed Treatment Short Course 
HIV             Human Immune Deficiency Virus 
MDR           Multi Drug Resistant 
MDGs          Millennium Development Goals 
MENA        Middle East and North Africa 
NGOs          Non - Governmental Organizations 
NTP             National TB Control Programme 
PTB             Pulmonary Tuberculosis 
TB               Tuberculosis 
ART            Anti-Retroviral Therapy 
CPT             Cotrimoxazole Preventive Therapy 
TBMUs       Tuberculosis Management Units 
WHO           World Health Organization 
 







1- Tuberculosis suspect. Any person who presents with symptoms or signs suggestive of TB. The 
most common symptom of pulmonary TB is a productive cough for more than 2 weeks, which 
may be accompanied by other respiratory symptoms (shortness of breath, chest pains, 
haemoptysis) and/or constitutional symptoms (loss of appetite, weight loss, fever, night sweats, 
and fatigue). 
2- Bacteriologically confirmed case of TB: A patient from whom a biological specimen is positive 
by smear microscopy, culture or WHO-approved rapid diagnostic test (such as Xpert MTB/RIF).  
3- Clinically diagnosed case of TB:  A patient who does not fulfil the criteria for bacteriologically 
confirmed TB but has been diagnosed with active TB by a clinician or other medical practitioner 
who has decided to give the patient a full course of TB treatment. This definition includes cases 
diagnosed on the basis of X-ray abnormalities or suggestive histology and extra-pulmonary cases 
without laboratory confirmation. Clinically diagnosed cases subsequently found to be 
bacteriologically positive (before or after starting treatment) should be reclassified as 
bacteriologically confirmed. 
4- Smear positive pulmonary TB (PTB) patients: patients with two or more sputum smears 
positive for AFB (acid fast bacilli) or one sputum positive for AFB and radiological abnormalities 
consistent with active TB as determined by the treating medical officer or one sputum positive for 
AFB and culture positive for AFB. 
5- Smear negative PTB patients: Patients with three smears negative for AFB and radiological 
abnormality consistent with active TB or failure to respond to antibiotic trials. 
6-  Case of pulmonary TB (PTB): Any bacteriologically confirmed or clinically diagnosed case of 
TB involving the lung parenchyma or the tracheobronchial tree. Miliary TB is classified as 
pulmonary TB because there are lesions in the lungs. Tubercles intra-thoracic lymphadenopathy 
(mediastinal and/or hilar) or tubercles pleural effusion, without radiographic abnormalities in the 
lungs, constitute a case of extra-pulmonary TB. A patient with both pulmonary and extra-
pulmonary TB should be classified as a case of pulmonary TB. 
7-  Case of extra-pulmonary TB (EPTB): Any bacteriologically confirmed or clinically diagnosed 
case of TB involving organs other than the lungs, e.g. pleura, lymph nodes, abdomen, 
genitourinary tract, skin, joints and bones, meninges. 
8-  New case of TB: A patient who has never been treated for TB or has taken anti-TB drugs for less 
than one month.  
9-  Previously treated case of TB: A patient who has been treated for one month or more with anti-
TB drugs in the past. Re treatment cases are further classified by the outcome of their most recent 
course of treatment into four categories: 1. Relapse patients have previously been treated for TB, 
were declared cured or treatment completed at the end of their most recent course of treatment, 
and are now diagnosed with a recurrent episode of TB (either a true relapse or a new episode of 
TB caused by reinfection). 2. Treatment after failure patients have previously been treated for TB 
and their most recent course of treatment failed i.e. they had a positive sputum smear or culture 
result at month 5 or later during treatment. 3. Treatment after loss to follow-up patients have 
previously been treated for TB and were declared ‗lost to follow-up‘ at the end of their most 
recent course of treatment. 4. Other previously treated patients are those who have previously 
been treated for TB but whose outcome after their most recent course of treatment is unknown or 
undocumented. 
10-  Case of multidrug-resistant TB (MDR-TB): MTB that is resistant to two first-line drugs: 
isoniazid and rifampicin.  




11- TB health facility is defined as any health institution with health care providers formally engaged 
in any of the following TB programme functions (DOTS): referring patients with presumptive TB 
or confirmed TB cases, laboratory diagnosis, TB treatment and patient support during treatment. 
12-  Patients’ delay: The time interval between date of onset of TB symptoms and first presentation 
to a professional health provider. 
13- Health system’s delay: The time interval between date of first presentation of patients to a 
professional health provider and initiation of treatment. 
14- Diagnostic delay: The time interval between the onset of TB symptoms and diagnosis of TB. 
15- Treatment delay: The time interval between date of diagnosis and initiation of treatment. 
16- Total delay: The time interval between date of onset of TB symptoms and initiation of treatment. 
17- Non-formal health providers: These include traditional health providers, local injectors and 
drug retail outlets. 
18- Formal health providers: Professional health providers working in modern health facilities i.e. 
hospitals, health centres, clinics owned by the government or the private sector. 
19- Self-treatment: Any kind of self-prescribed treatment taken by patients for their illness. 
20- Case detection rate: is calculated as the number of new cases reported to NTPs in a given year 
divided by estimated incidence for the same year. The CDR is thus a ratio rather than a rate, but in 
the context of this indicator the term ‗rate‘ has become standard terminology. 






Globally, tuberculosis (TB) is second to HIV/AIDS as a cause of illness and death of adult (1)(2)]. In 
2013, an estimated 9.0 million people had TB with 1.5 million deaths (including 360 000 of whom 
were HIV-positive)(3). TB occurs in every part of the world, the largest number of new TB cases 
occurred in the South-East Asia and Western Pacific Regions, accounting for 56% of the new cases 
(1)(3). The efforts through effective diagnosis and treatment had succeeded to save 37 million lives 
between 2000 and 2013 (3). However the death from the disease is still unacceptably high given the 
fact that deaths from TB are preventable (3) . With strong TB control programme many of these 
deaths could be avoided. 
 
1.1Problem statement  
The goal of Tuberculosis control is to stop disease transmission, thereby reduce mortality and 
morbidity rates (4)(5). Identification of transmission determinants such as number of incident 
infectious cases and durations of their infectiousness is mandatory to effectively control, since without 
detection the smear–positive index case is found to infect around 30%–40% of his contacts (6)(7). 
Early case detection and proper treatment will reduce the time of infectiousness of this case in the 
community and hence the number of new individuals exposed and infected (7). On the other hand, 
delay in case detection which eventually cause delay in diagnosis may worsen the disease, increase 
the risk of death and enhance tuberculosis transmission in the community. Unfortunately, in 
developing countries early case detection of TB had never gained its expected place in the strategies 
of national tuberculosis control programmes, in spite of the scale up of quality-assured TB services in 
line with the Stop TB Strategy (8). 
In developing countries, almost all national tuberculosis control programs depends on passive case 
detection which is based on diagnosing infectious cases whom present themselves to the health 
facilities (8). This type of case detection is known to be influenced by factors such as patient 
motivation, the degree of diagnostic suspicion by health workers and the quality of laboratory 
facilities (9)(10).  In fact passive case detection by definition is considered to be a major source of 
delayed diagnosis (11). These delays may be attributed to both patients as well as the health care 
system (11). 
The patients may delay seeking help or the health care system may delay in suspecting and 
investigating for TB. Patient‘ delay is the period between onset of TB symptoms to first visit to any 




health provider (health seeking period) (7). The health seeking is a very complicated process and is 
influenced at many levels by patient‘s socio-economic factors, social interactions, and the health 
system related factors (6). on the other hand, the Health system‘ delay: Period from the date of the 
patient's first contact with the health care service to the initiation of treatment (7). This period is 
influenced by several factors such as; prevalence of TB, accessibility of health facilities, patient‘s 
socio-demographic characteristics, symptoms on presentation, presence of refined suspicion index, 
infrastructures and organization of the health system (6). TB control programs must understand the 
reasons behind these delays in order to achieve their goals successfully (7). However in almost all 
MENA countries, the national TB control programmes are able to detect on average one third of 
smear-positive tuberculosis cases (7). The remaining two thirds will thus continue to transmit TB 
infection in the community until detected by other health sectors (7).  
The Middle East and North Africa region (MENA), is an economically diverse region comprising 
both the oil-rich economies in the Gulf and the countries that are resource-scarce in relation to 
population, such as Egypt, Morocco, and Yemen [14,15]. The World Bank‘s account of the MENA 
region covers the 21 members of the Arab League, and Iran, Israel, and Turkey [16]. The region is 
known for its unusual cultural homogeneity represented in its linguistic, religious, socio-cultural, and 
historical references [17]. The Arab spring phenomenon has been impacted these countries in the last 
half decade and draw marked changes in the Health Delivery. 
 
1.2 Justification for this review  
 
Three earlier systematic reviews have addressed the delay of TB diagnosis and treatment [18-20].  
However, none of these reviews were specific to the MENA region or are in need of updating since 
the time of publication.  We will be conducting this review to summarize the most recent evidence for 
factors associated with both patient and health system delay in diagnosis and commencing treatment 
for PTB in the MENA region. 
 
1.3 Research question: 
What are the factors associated with patient and health system delay for diagnosis and treatment of 
tuberculosis in Middle East and North Africa (MENA)? 





2.1 Primary Objectives: 
 To study factors associated with patient and health system delay for diagnosis and initiation 
of treatment of pulmonary tuberculosis in Middle East and North Africa (MENA). 
 
2.2 Secondary Objectives: 
 To determine the magnitudes and contributions of patient period in the total pre-treatment 
period. 
 To determine the magnitudes and contributions of health system period in the total pre-
treatment period. 
 To determine the magnitudes of total delay. 
 
3. METHODS 
  3.1 Criteria for considering studies for this review  
 
  3.1.1 Types of studies:  
Observational studies: case control studies, cross sectional studies and population based studies. In 
case of Randomized control trials (RCTs), cluster-randomized control trials (cRCTs), controlled 
before-and-after studies (CBAs) and cohort studies (prospective and retrospective) studies, we will 
only use baseline population data. 
3.1.2 Type of Participants: 
TB patients (or suspected TB patients) defined as: 
1. All chest symptomatic individuals with cough ≥2 weeks and suspected for TB, 
2. Pulmonary TB (PTB) patients (smear-negative, new smear positive or re-treatment 
patients),  
3. Pulmonary and extra-pulmonary TB (EPTB) (if data were presented for PTB separately). 
 
3.1.3 Types of outcome measures: 
3.1.3.1 Primary outcome:  
1. Factors associated with patient and health system delay 





3.1.3.2 Secondary outcome: 
1. Patient delay, defined as the time interval from onset of TB symptoms to first visit to 
any health provider.  
2. Health system delay, defined as the time interval from the first health provider visit to 
initiation of treatment such as: 
 Diagnostic delay is the time interval between the onset of symptoms and 
labeling of the patient as tuberculosis patient (tuberculosis diagnosis). 
 Treatment delay is time interval between tuberculosis diagnosis and initiation of 
anti-tuberculosis. 
3. Total delay is the time interval from the appearance of major of TB symptoms to 
initiation of treatment. 
 
3.2 Search methods for identification of studies: 
A comprehensive search to identify both published and unpublished articles with the relevant studies 
with no language and time limit will be performed. The search strategies for electronic databases will 
incorporate both medical subject headings (MeSH) and free-text terms and will be adapted to suit 
each individual database using applicable controlled vocabulary (see appendix 1). 
3.3 Electronic searches 
Relevant studies will be searched for and identified from electronic databases including; Cochrane 
Central Register of Controlled Trials (CENTRAL), Web of Science, PubMed, CINAHL, Psychlnfo, 
Scopus, Index Medicus for the Eastern Mediterranean Region (IMEMR), (Africa-wide) allied health 
and Google scholar. 
In addition, we will identify conference proceedings and reference lists of relevant articles. 
 
3.4 Data collection  
    3.4.1 Selection of studies:  
 
Two authors will screen titles and abstracts to select potential eligible studies. Thereafter, the full text 
of potentially eligible studies will be obtained and the final selection for inclusion into the review will 
be conducted by two independent authors. Any disagreements regarding inclusion of studies will be 
resolved by discussion or by consulting a third author. A PRISMA flow chart will be used to 




summarize the search and selection of studies for the review. A table of all included studies will be 
included in the final review and the reasons for exclusion of studies will also be documented. 
 3.4.2 Data extraction and management: 
Data will be extracted from selected studies independently by two authors using standardized data 
extraction forms (see Appendix 2). Disagreements on study selection and data extraction will be 
resolved by consensus between the two review authors, failing which a third author will arbitrate. 
Prior to use, the extraction form will be piloted on at least five studies identified randomly from the 
list of included studies.  For each study report, we will extract available information on the setting, 
method of obtaining the study sample, sample characteristics, study design, data collection method, 
measure of the dependent variable, data source(s), data collection method(s) and instrument, and 
findings. Findings will include all variables tested for an association with delay. 
 
3. 5 Data analysis and synthesis: 
We will express the result of each study as a risk or an odd ratio with its corresponding 95% 
confidence interval for dichotomous data or mean difference with its standard deviation for 
continuous data. We will group studies that compare broadly similar types of outcome to get feasible 
results on an overall estimate of effect. Random effects meta-analysis will be preferred due to 
anticipated heterogeneity in study results. We will derive SEs where studies have provided the 
corresponding numerator and denominator for delay of TB prevalence estimates. We will consider 
non-overlapping CIs as an indication of statistically significant differences. Prevalence of TB delay 
from different studies will be pooled in a meta-analysis using Review Manager 5.3. If we encounter 
variation in reported outcome measures between studies, we will not pool the results but summarize 
the findings in a narrative format. 
 
3. 5.1 Assessment of risk of bias in included studies:    
 
The quality assessment tool by Hoy et al. 2012 [21] for observational studies that are modified by 
Werfalli and colleagues [22] to allow for a composite score that assist with relative comparison 
between the studies will be applied a to all screened full reports in order to code eligibility decisions 
and to assess study quality and agreement between investigators. The scoring system tool categorizes 
high risk studies as those with an overall score of 0-5 points, moderate risk as 6-8 and low risk >8 
points see table 1. 
 




Table 1: Quality assessment tool [21] modified by [22] 
Items  Quality 
Score 
External Validity (4 points) 
1. Was the study's target population a close representation of the national population in relation to 
relevant variables? 
(1 point) 
2. Was the sampling frame a true or close representation of the target population?  (1 point) 
3. Was some form of random selection used to select the sample, OR was a census undertaken?  (1 point) 
4. Was the likelihood of nonresponse bias minimal?  (1 point) 
 
Internal Validity (6 points) 
1. Were data collected directly from the subjects (as opposed to a proxy)?  (1 point) 
2. Was an acceptable case definition used in the study?  (1 point) 
3. Was the study instrument that measured the parameter of interest shown to have validity and 
reliability?  
(1 point) 
4. Was the same mode of data collection used for all subjects?  (1 point) 
5. Was the length of the shortest prevalence period for the parameter of interest appropriate?  (1 point) 





0-5 points  Low Risk: Further research is very unlikely to change our confidence in the estimate 
6-8 points  Moderate Risk: Further research is likely to have an important impact on our confidence in the 
estimate and may change the estimate 
>8 points  High Risk: Further research is very likely to have an important impact on our confidence in the 
estimate and is likely to change the estimate. 
 
3. 5.2 Assessment of heterogeneity: 
We anticipate substantial variation in study results due to differences in study designs, populations, 
and onset of symptoms, first appropriate health care provider, definition of TB delay used by authors 
and health system status (also TB transmission and burden in different countries). We will examine 
statistical heterogeneity between study results using the Chi-squared test of homogeneity (with 
significance defined at the alpha-level of 10%), and quantify any statistical heterogeneity between 
study results using the I-squared statistic [23]. 
 
3. 5.3Dealing with missing data: 
If necessary, we will contact the corresponding authors of included studies to give us any missing 
data. We will describe missing data for each included study and discuss the extent to which the 
missing data could alter our results. 
 
3. 5.4 Sub-group analyses 
 




Subgroup analyses may be conducted if possible, taking into account but not limited to age, gender, 
socioeconomic characteristics, attitudes and beliefs of the target population toward TB, definition of 
delay, HIV/TB co-burden, setting of the studies and country income status. We will use the Chi2 test 
for subgroup differences to test for subgroup interactions. 
 
 
3. 5.5 Grading the quality of evidence 
The GRADE approach will be used to assess the quality of evidence related to each of the outcomes. 
The GRADE approach will assess the quality of evidence as very low, low moderate or high, with 
implications on how confident we can on the results and if further research is likely to change the 
results [24].  
4. ETHICS 
 
Systematic reviews draw on publicly available secondary data and, therefore do not require formal 
ethical review [25]. It is noted that ethical research, even if secondary research, relies on scientific 
validity. The study will be guided by experts with knowledge of content and methodology. The results 
of this review will be available online through the university library. The review will also be written 
up for submission to a peer reviewed journal. 
5. FUNDING 
 
No funding is expected for this review. 
6. DISSEMINATION 
 
The study will be disseminated by peer-review publication and conference presentation.
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PART B: LITERATURE REVIEW  
 






Tuberculosis (TB) remains one of the world‘s deadliest communicable diseases [1-4]. In 2013, about 
64 per cent of the estimated nine million people who have developed TB were detected as newly 
diagnosed cases. It is estimated that this figure omitted about 3 million cases that were either not 
detected, or not reported to national TB programs (NTPs) [4]. This problem related to the low 
detection rate of TB is one of the major difficulties confronting TB control worldwide. In almost all 
Middle Eastern and North African (MENA) countries, the national TB control programmes can 
identify on average one-third of smear-positive TB cases [5]. The remaining two-thirds will thus 
continue to transmit TB infection in the community until detected by other health sectors. This 
overview precedes the systematic review and is structured according to the following sections:  
- Background, health systems status, disease burden and TB situation in the MENA region. 
- TB control: goals, target, and challenges. 
- The challenge of low case detection rate in developing countries. 
- The health seeking behaviour among TB patients. 
- Overview of TB delay and its consequences.  
- Levels of delay in the diagnosis and treatment of TB (total, patient and health system delays). 
- Certain factors associated with delay in TB diagnosis and treatment 
 






Articles used in this overview were obtained from scholarly resources, such as PubMed 
(http://www.ncbi.nlm.nih.gov/pubmed/) and Google Scholar (http://www.scholar.google.co.za/). A 
wide range of keywords such as tuberculosis, epidemiology, tuberculosis delay and case finding for 
TB without language restriction were used to retrieve relevant articles for each topic. We searched the 
literature between 1995 -2015, we choose this period because the issue of TB delay has gained 
considerable attention within the last 20 years. 





1. OVERVIEW OF THE MENA REGION 
1.1 Background  
The Middle East and North Africa region (MENA) is an economically diverse region comprising the 
oil-rich economies in the Gulf and countries that are resource-scarce in relation to population, such as 
Egypt, Morocco, and Yemen [6,7]. The World Bank‘s account of the MENA region covers the 21 
members of the Arab League (Algeria, Bahrain, Djibouti, Egypt, Iraq, Jordan, Kuwait, Lebanon, 
Libya, Mauritania, Morocco, Oman, Palestine, Qatar, Saudi Arabia, Somalia, Sudan, Syria, Tunisia, 
The United Arab Emirates and Yemen), Iran, Israel, Armenia, Azerbaijan, Georgia and Turkey [8-10] 
(Figure B1). The region, known for its unusual cultural homogeneity, is represented in its linguistic, 
religious, socio-cultural, and historical references [10]. Also, the region is at the intersection of the 
trade routes connecting Europe and China, India and Africa, and all the cultures of the Mediterranean 
basin. The area accounts for 7 per cent of the world‘s population numbering 351.4 million in 2014 
[11]. 
 
Figure B1: Middle East and North Africa map (Resource reproduced from slide share available at 
http://www.slideshare.net/Presentationsat24point0/map-of-mena-14114848. According to World Bank, 
countries in orange are commonly accepted as MENA‘s countries whereas countries in grey (Turkey, Armenia, 
Azerbaijan, Georgia, North Sudan, Somalia and Mauritania) are only sometimes accepted. However, for this 
review, we considered all the countries on the map to be eligible.   
 
The region has one of the fastest-growing populations in the world with higher birth rates than death 
rates. The demographic projection articulates that the region‘s youth population (up to 24 years old) 




will grow steadily by about 2 million by the end of 2015, then increase by about 10 million between 
2015 and 2030 [11]. Many countries adopted active population policies that contribute significantly to 
reducing the fertility rates, starting from a regional average of over six births per woman in 1980 to 
below four in 2003 [12]. This decline in fertility rates does not avoid the problem that despite 
mortality rates, the region is challenged by a rapidly expanding youth population and a smaller growth 
rate in the ageing population [12]. Another challenge related to demographic transition is the 
population movement. Conflicts, wars, natural disasters and political instability have led to 
displacement, forced migration and outpourings of refugees. In relation to TB, these demographic 
transitions virtually ensure that the number of TB cases will increase over the coming years [13].   
The regional epidemiological transitions result from the effects of rapid urbanisation, changes in 
tobacco consumption, diet and decreasing burden of communicable diseases with an increase in 
chronic diseases and injuries [12]. In terms of smoking, the age-standardized prevalence of current 
tobacco smoking in persons aged 15 years and over in the region is 39 per cent ranging from 15.3 per 
cent in Morocco to 53.9 per cent in Lebanon. Furthermore, smoking-related mortality rates are 
expected to rise to 9·5 per cent in 2020 from the current estimate of 2.4 per cent [14]. Further 
changes in nutrition have led to the region being challenged by the high prevalence of individuals 
suffering from stunting, iron-deficiency anaemia and morbid obesity. Road traffic related mortality is 
among the highest in the world (26·4 per 100 000 population compared with 19 per 100 000 for the 
world as a whole) [12]. The disease burden is discussed later in this chapter.  
 
Both demographic and epidemiological transition increased the demand for many services such as 
educational and health services at all levels and will place enormous pressure on existing systems. 
Furthermore, threats from rapid urbanization, smoking, malnutrition and overpopulation, together 
with migration, political instability, rising unemployment and low economic growth (in most of the 
region‘s countries) must be considered. The impact of these factors on the health of populations in 
general and TB, in particular, is unimaginable. Consequently, there is an urgent demand for stronger 
public health systems that encompass the needs and expectations in terms of both quality and 
quantity. Fortunately, in the wake of the Arab Spring, the demands for greater accountability and 
more responsive public service delivery echoed across the Region [15].   
 
The Arab revolution that started in December 2010 called for freedom, social justice and 
improved accountability for a dignified life and well-being. This phenomenon, recognizable in 
the name of the Arab Spring, impacted almost all MENA‘s countries and caused marked changes 
in the qualities of life  [16]. Although most attention focuses on security and political 
developments, there are substantial consequences for population health. These include immediate 
problems, such as violent deaths and injuries, population displacement and damage to essential 




infrastructures. Longer-term weaknesses still to be debated in the political changes include high 
unemployment, the low status of women, erosion of already weak welfare systems and rising 
food prices. The health system in the region is expected to be severely devastated by the crises 
now and in the coming years [16]. Indeed, all these problems provide an environment where TB 
is very likely to occur [17,18]. It is vital to establish structures to contain the potential increase in 
numbers of TB in these circumstances and prevent a repeat of the mistakes made in countries that 
have undergone similar rapid political transition [16]. 
 
1.2 Public health care System in the region 
All aspects of health systems are suffering from the pressure placed upon them by the continuously 
increasing demands due to demographic and epidemiologic transitions with technological advances 
and rising public expectations. The political instability contributed to emergency situations (the 
sectarian war and Arab spring), and economic sanctions have stretched resources beyond the systems‘ 
ability to cope, quality is reduced and services defined as ―below standard.‖ [19]. However, most 
countries in the MENA region are in the process of making an attempt to reform their health care 
systems in a responsible manner. Unfortunately, most are financially motivated rather than needs 
driven and are based on the United States or European models that are not contextualized to meet the 
needs of the countries concerned. This has led to the rapid and unregulated expansion of the private 
sector in these countries focussing mainly on curative medicine, but not preventive medicine or a 
public health agenda. Limited resources available for badly needed public health programmes are 
further squeezed as a result [19]. 
WHO states that there are six elements necessary to create a health system:  leadership and 
governance, health care financing, health workforce, medical products and technologies, information 
and research and, service delivery [20]. These elements are essential to achieve the goals of a health 
system for better health, awareness and response to the needs of the communities and financial 
protection against high medical service costs (Figure B2). Jabbour et al. 2012 examined the health 
system based on these elements and concluded that the health system in the region is very poor and 
does not meet the basic criteria (ensuring equity, universality, comprehensiveness and free service at 
point of delivery [21]. The current health system in the region is not satisfactory and lacks the 
commitment to promote the equity. Furthermore, in countries where the health system has been 
destroyed, the opportunities for an equitable health system is very limited. In those countries where 
the health system is progressing towards universal coverage (being able to provide health services to 
its citizens) i.e. Gulf countries, the migrant domestic and expatriate individuals are excluded [21]. 




The issue of health equity is mainly associated with health care financing. Despite the fact that most 
MENA countries are classified as middle-income countries, their health systems are not delivering 
results proportionate to wealth levels [22]. Government financing for health is very low; the World 
Bank reports that MENA countries have some of the lowest levels of government spending on health 
care. 
 
Figure B2: This conceptual WHO Health Systems Framework illustrates the building blocks for a good health 
system and the outcomes that might be achieved if these blocks were implemented. Source; WHO/WPR 2014 
On average, MENA governments spend 8.2 per cent of their budget on health care compared to 80 per 
cent on the military forces in some countries. For instance, in 2011, Saudi Arabia and the United Arab 
Emirates, considered as wealthy countries, spent 2.3 per cent and 4.1 per cent respectively of their 
gross domestic product (GDP) on health care. This resulted in high costs for families in the region 
who have to pay almost 40 per cent of all health care costs [22].  
It is significant that the issue of the delays in the diagnosis of TB, particularly in the health system and 
this contribution to the total delay in these cases could help analyse the quality of the health system. 
For example, three studies conducted in different time periods in Turkey found that delayed action in 
the health system it‘s the main source of TB delay  in identifying the disease early and making it more 
treatable [23-25]. Health care providers were slow to suspect TB and the tools available for its 
investigation and diagnosis are often underutilized. Another multicentre study [5] identified on 
average five health care providers in the region available to TB patients for treatment (range= 2-12) 
and a minimum of two visits to each patient before a diagnosis of TB is confirmed. Also, the 
accessibility of the health facility was another significant predictor of delay in Egypt, Syrian Arab 
Republic and Yemen, where patients travel for more than half an hour to reach the health facility. 
These poor quality services by the public health system force patients to seek alternative care at 
private health care providers, including homeopaths or traditional healers [5].  





1.3 Public health service delivery in the region 
Regrettably, none of MENA‘s countries can be defined as having a well-developed public health 
delivery system. They are at different stages in the development of their public health infrastructures 
and capabilities and there are variations between countries in terms of their capabilities. Nevertheless, 
addressing inadequate capacity and insufficient resources allocated to preventive health services or a 
wider public health agenda in comparison to acute services, despite the major public health challenges 
mentioned, is not stated as a problem in the region [19]. Table B1 summarizes variations among some 
MENA‘s countries concerning: 
 
 Service or academic orientation public health: Academic public health deals with teaching 
and research, supporting service departments of public health at the national and local levels 
and complementing the service of public health to provide high-quality delivery for the 
nation. 
 The level of function: As noted on the Table B1 according to the World Bank, the overall 
level of function in the region is poor. However, some countries are in the process of 
improving this, but there are many obstacles faced by these countries in constructing better 
public health capabilities. These include long-term public health initiatives created by 
politicians and policymakers who may be more interested in quick and immediate returns 
that can translate into political gain. Lack of reliable data on population, lifestyles, 
behaviours, risk factors, and the activities and performance of the health system are further 
obstacles to designing relevant and timely interventions.  
 Funding for public health function there are variations in the type of funding available to 
the public health service. In some countries, it is part of the general allocation to health and 
cannot be defined separately while in the other countries it is well defined (see Table B1). 
Furthermore, epidemiological and public health research is almost non-existent in most 
countries due to a lack of funds. This reduces the ability of both academic and service 
departments in their attempts to address the nation‘s health problems and achieve the best 
solutions based on the evidence. 
 Higher medical training for public health practitioners: The development of the Arab 
Board of Medical Specializations (a residency programmes for training in most medical and 
surgical specialties) in 1970s by the Council of Arab Health Ministers is one of the most 
significant efforts to establish, apply, maintain and monitor high standards for medical 
specializations. Currently, 14 of the 24 MENA countries participate in the Arab Board 




training and residency programme (Table B1). The countries that are not part of the Arab 
Board are running their systems that are possibly similar to the Arab Board [19]. 
 
In spite of these difficulties, there are some impressive efforts in progress to strengthen the health 
system and the delivery of these services in the region. The public health systems have been reviewed 
by WHO, the World Bank, the Arab Board, United Nations Children's Fund (UNICEF), the European 
Union, the US Agency for International Development, the UK Department for International 
Development, as well as other international and national organizations. As a result, there is financial 
and technical support being made available to strengthen the system‘s function [19]. 





Table B1: Public Health Infrastructure and Function in MENA/EM Countries 
Country Infrastructure Function  Funding Training 
Bahrain Academic + service  Medium   Not well defined Arab Board 
Djibouti  Service  Weak Not known  — 
Egypt  Academic + service  Relatively 
strong  
Generally not well 
defined 
1. Academic diplomas 2.Plan for 
Egyptian National Board 3. Arab Board 
Iran  Academic + service  Strong Defined Academic diplomas, master‘s, PhD 
Iraq  Service + academic  Relatively 
strong 
Some public, health 
services defined 
separately 
1. Arab Board 2. Iraqi National Board 
3. Academic diplomas, master‘s, PhD 
Jordon  Academic + service  Weak Not well defined 1. Arab Board 2. Jordanian National 
Board, 3. Academic diplomas, master‘s, 
PhD. 
Kuwait  Service  Strong Defined 1. Arab Board, 2. Academic 
Lebanon  Academic  Weak Not well defined 1. Arab Board, 2. Academic diplomas, 
master‘s, PhD 
Libya  Academic  Weak Not well defined Arab Board 
Morocco  Academic + service  Medium Defined Specializations diploma 
Oman  Service  Developing Defined Arab Board 
Qatar  Service  Developing Defined Arab Board 
Saudi 
Arabia  
Service + academic  Medium  Defined 1. Arab Board, 2. Saudi National Board  
Sudan  Academic  Weak/limited Not well defined 1. Arab Board (but no Community 
Medicine as yet), 2. Academic  
Syria Academic (in the process 
of developing service 
public health)  
Weak Not well define 1. Arab Board 2. Low professional 
diploma, 3. Academic diplomas 
Tunisia  Academic + service + 
research  
Strong Defined 1. Tunisian National Board, 2. 
Academic diplomas, master‘s, PhD. 
United 
Arab  
Service  Strong Well defined Arab Board  
West 
Bank 
Academic + service  Developing Not well defined 1. Academic diplomas, 2. Some trainees 
were offered places on the Arab Board 
in other Arab countries.  
Yemen  Academic + service  Not known Not known 1. Arab Board 2. Academic diplomas, 
master‘s 
No available information for Algeria and Somalia 
Adapted from [19] 
 





1.4 Disease burden in the region 
The MENA region faces problems related to disease that can be divided into two parts; the declining 
burden of communicable diseases (CDs) and an increasing burden of non-communicable diseases 
(NCDs). Figures reveal that the CDs declined from 40 per cent in 2000 to 29 per cent in 2010, while 
the NCDs rose from 45 per cent to 53 per cent over the same period [26].  
NCDs are the cause of many more premature deaths and disabilities (also known as disability-
adjusted life years or DALYs) than in the past as shown in Figure B2 below [27]. Approximately, 65 
per cent of the region‘s deaths among people aged 45-60 are due to cardiovascular diseases and 
cancer. According to WHO Global Status Report on NCDs in 2010, NCD deaths in the region are 
expected to increase by 20 per cent by 2020 if the trend is not reversed or at least stopped [28]. The 
main risk factors responsible for NCDs include tobacco consumption, unhealthy diet, physical 
inactivity and harmful alcohol consumption [28]. According to the WHO, the national health systems 
capacity for prevention and control of chronic diseases in the region is insufficient due to limited 
resources, fragmented and uncoordinated approaches to chronic care, low commitment to prevention, 
lack of surveillance systems, absence of clear policies and inadequate treatment guidelines [12].  
As previously mentioned the health care systems in the region focus mainly on acute care, where the 
patients who present at the hospital are usually severely ill or suffering from long-term complications. 
The health system responds by treating and discharging the patients, and if needed, the patients may 
be offered a follow-up appointment. In reality, these chronic conditions require a coordinated, 
comprehensive system that integrates acute and chronic care effectively [12]. In order to overcome 
this problem, a few countries such as Morocco have developed a long-term care strategy for diabetic 
patients. The solution for meeting the increasing demand for NCDs care in the twenty-first century 
will be the associating of public health to health care, and the provision of individual care in a manner 
that impacts population health [12].  
In regard to CDs, approximately all MENA‘s countries have achieved high rates of immunization 
coverage (80 to 100 per cent) for all vaccine-preventable diseases and made good improvements 
according to survival indicators.  According to UNICEF and World Bank, the infant mortality rate has 
declined from 44 deaths per 1 000 live births in 2004 to 21.3 deaths per 1 000 live births in 2013 and 
the life expectancy at birth has increased from about 68 years in 2004 to an average of 72 years in 
2013 [29,30]. However, newer CDs such as HIV/AIDS are emerging and will provide new 
challenges. 





Figure B3; DALYs in the Middle East and North Africa, source Institute for Health Metrics and Evaluation 
(IHME). Resource reproduces from http://www.humanosphere.org/basics/2013/09/visualizing-the-burden-of-
disease-in-the-middle-east-and-north-africa/. Bars on the right show the percentage by which DALYs have 
increased since 1990 and bars on the left show the per cent by which DALYs decreased. Most communicable 
diseases declined between 1990 and 2010, as shown by the red bars. And the non-communicable diseases and 
injuries increased as shown in blue and green bars respectively.   





1.5 HIV/AIDS in the region 
The MENA region accounts for only 2 per cent of the estimated global number of people living with 
HIV [31]. In 2014, there were 240 000 (150 000-320 000) people living with HIV in the region and 12 
000 (5300–24 000) AIDS-related deaths [32]. However, recent estimates show that MENA is one of 
two regions with the fastest growing numbers related to the HIV epidemics. Between 2001 and 2014, 
there was a 26 per cent increase in the diagnosis of new HIV infections and AIDS-related deaths more 
than trebled in the region. This could be attributed to many causes and the most significant of these is 
the lack of availability of treatment (14 per cent) [32]. In addition, insufficient commitment, stigma, 
discrimination and inappropriate laws continue to obstruct the work carried out for those living with 
HIV and people on the margins in the MENA region [31]. There is also a shortage of data on HIV in 
countries across the region, as only four countries have effective HIV surveillance systems enabling 
them to track their epidemics. This makes it difficult to get an accurate picture of the situation, both 
regionally and nationally [33]. 
 
HIV/AIDS among TB patients is a useful indicator of the maturity of the HIV epidemic in a given 
setting because it reflects the presence of advanced HIV or AIDS cases in the population [33]. TB is 
considered a leading cause of death in HIV-infected patients and accounts for 25 per cent of HIV-
related deaths [1,3,4,34]. The issue of TB diagnosis and treatment delays in HIV co-infected patients 
is addressed in many studies, especially in countries where HIV is prevalent [35,36]. However, it is 
difficult to make any conclusions in this regard in the MENA region due to the scarcity of HIV 
statistics. 





OVERVIEW ON TUBERCULOSIS EPIDEMIOLOGY 
 
1.1 BACKGROUND  
Human TB is caused by infection with Mycobacterium tuberculosis, which is acid-fast bacilli and a 
member of Mycobacterium complex. Broadly, TB can be classified into two main types:  Pulmonary 
TB, which is the most common and involves the lung parenchyma and/or hilar lymph nodes. Extra-
pulmonary TB can present with, or without, the pulmonary form; it affects many organs or tissues 
other than the lung parenchyma, such as the pleura, meninges, extra-pulmonary lymph nodes, 
intestines, kidneys and bones. Individuals with pulmonary TB produce airborne droplets while 
coughing, sneezing, or talking. Inhaled infectious droplets lodge in the alveoli where the bacilli are 
taken up by macrophages. Then there will be a series of reactions that result in either containment of 
the infection or progression to active disease [37].  
Inside macrophages, M. tuberculosis replicates slowly but continuously, and spreads through the 
lymphatic system to the hilar lymph nodes. Thereafter, a process called phagocytosis occurs, where 
the phagocytes (neutrophil and macrophages) engulf many of the bacteria and TB-specific 
lymphocytes destroy the bacilli and normal tissue. This immune reaction will result in the forming of 
granulomas (which are new tissue masses of live and dead bacilli surrounded by a protective wall of 
macrophages) that will limit the further replication and spread of bacilli. Unless a later defect occurs 
in cell-mediated immunity, the infection remains within the granulomas [37]. The bacteria remain 
dormant and in this stage it is called a Latent TB infection. 
The cases with latent TB infection don‘t show any symptoms related to TB but come up positive in 
Tuberculin Skin Tests (TST) and Interferon-Gamma Release Assays (IGRA) blood tests. Cases with 
latent TB infection can progress to full-blown TB disease through either endogenous reactivation of 
the latent bacilli, or exogenous reinfection with a new strain. In the absence of other predisposing 
conditions, only about 5 per cent of infected people develop the progressive primary disease within 
five years of infection [37]. 
In cases where the immune response are not able to contain the replication of Mycobacterium, 
primary progressive TB disease will develop with symptoms (mainly coughing with night sweats for 
more than two weeks) and become a source for transmitting the disease within the community. 
 





2.2 TB Transmission 
 
Tuberculosis transmission depends upon exposure to tubercle bacilli. There are three major factors 
that determine the risk of becoming exposed: 
1) The number of incidents of infectious cases in the community. The higher the number of 
these cases, the higher the risk of transmission [38].  
2) The number and nature of interactions between a TB case and a susceptible contact per unit of 
time of infectiousness. This is influenced by many factors. These include population density 
(low levels of infectiousness in rural settings), family size, climatic conditions (low TB 
transmission in a warm climate because people stay in well-ventilated places) and age of the 
patient. The latter affects the pattern of social participation; all age groups socialize together 
and this may introduce TB transmission among specific age group [38].  
3) The duration of infectiousness. A period of two months is enough for the infection to spread 
to domestic contacts. In addition, without treatment, 50 per cent of TB patients will die within 
five years and on average, the patient who is the source of infection will infect 10 to 15 
people per year (WHO 2014). Most transmission of TB occurs between the appearance of a 
cough and initiation of treatment [38]. The patient becomes more contagious as the delay 
progresses, the length of which is positively associated with the bacillary number in sputum 
smear [39]. 
 
2.3 Risk factors for TB 
There are numerous risk factors associated with the development of TB such as the presence of HIV 
infection, underlying health conditions such as diabetes mellitus and cancer, close contact with TB 
infected individuals, age (with the young and elderly being particularly vulnerable due to weak 
immunity), smoking, alcoholism and poverty [40].  
 
2.4 TB Diagnosis 
 
A complete history, physical examination, tuberculin skin test, acid-fast bacillus (AFB) smears, chest 
X-rays and sputum culture are used to diagnose TB. During the taking of the history, the patient may 
reveal contact with someone who has been diagnosed with TB. The health provider needs to take a 




full medical history including the duration of symptoms, any other medical conditions and a history of 
medical problems and diagnoses [41]. The tuberculin test measures the delayed hypersensitivity 
response to an injection of purified protein derivative by producing a local skin reaction within 48 to 
72 hours of injection into the skin of an infected person. The tuberculin skin test is a great diagnostic 
tool as a screening test, as a strong positive skin reaction indicates the presence of viable tubercle 
bacilli in the body [42]. Sputum specimens will be checked under a microscope for rapid diagnosis 
and culture. Smears are taken to check for acid-fast bacilli that have a waxy capsule, which is stained 
with difficulty using red dyes that give the bacilli red look when examined under the microscope. 
Culture examination is more accurate than microscopy but it takes much longer to obtain results, 
usually about six weeks [4].  A chest X-ray of a person infected with TB may reveal lesions in the 
upper lobes of the lungs and useful for the evaluation of patients who have negative sputum smears to 
confirm pulmonary TB and  identify other abnormalities that may be responsible for the symptoms 
[4]. 
 
2.5 TB Globally 
Globally, TB is second to HIV/AIDS as a cause of illness and death of adults [1-3,34]. In 2013, an 
estimated nine million people were infected with TB resulting in 1.5 million deaths (including 360 
000 of whom were HIV-positive)[4]. TB occurs worldwide. The largest number of new TB cases 
were identified in South-East Asia and Western Pacific Regions, accounting for 56per cent of the new 
cases [1,4]. The efforts made for effective diagnosis and treatment have succeeded in saving 37 
million lives between 2000 and 2013 [4]. However, the death from the disease is still unacceptably 
high, given the fact that deaths from TB are preventable [4,43]. Many of these deaths could be 
avoided with a stronger and more efficient TB control programme. 
 
2.6 TB in MENA region  
According to World Bank estimates, this region is responsible for about 6–7 per cent of the global 
burden of TB [44]. In 2013, the estimated number of incident TB cases in the region was 40 per 
100,000 people. The incidence of TB is calculated by the estimated number of new pulmonary, smear 
positive and extra-pulmonary tuberculosis cases. The rate of decline of patients with TB has reduced 
very slowly with less than 1 per cent per year from 1990 [45]1. However, ten countries have reduced 
their numbers of individuals with TB to rates of less than 25 per 100 000 populations in 2010, 
compared to only one country in 1990. According to WHO, seven countries (Sudan, Morocco, 
                                                        
1 Eastern Mediterranean Region (EMR) is one of WHO‘s six regions include all MENA countries plus 
Afghanistan and Pakistan. We exclude the data for these countries from the final figures. 




Somalia, Iraq, Egypt, Islamic Republic of Iran and Yemen) were responsible for 95 per cent of the TB 
burden in the region in 2010 [45].  
Related to multi-drug resistance TB (MDR/TB), the region has very low rates of MDR about 3.5 per 
cent, however, it is estimated that 12 per cent of MDR-TB cases have been identified and 72 per cent 
of these cases is on treatment on 2013 [45]. Furthermore, since 1994 only eight countries in the region 
have reported MDR/TB data from areas representing only 22 per cent of all tuberculosis cases. The 
primary limiting factor to expanding survey coverage is the high number of countries currently facing 
conflict and complex emergency situations [46].  
The national governmental contribution to NTPs budgets varied in different countries. In Djibouti, 
Somalia and Southern Sudan, NTPs relied entirely on external donors such as the Global Fund to 
Fight AIDS, TB and Malaria (GFATM). In countries from the Gulf Cooperation Council (GCC), the 
governments are responsible for all the NTPs budgets while in the remaining countries, the 
governmental financial contribution ranged from 30 per cent to 50 per cent of the planned budget 
[46]. In terms of TB treatment, all countries in the region use standardized treatment regimens in line 
with the internationally recommended guidelines. Additionally, all countries have DOTS in place, at 
least during the intensive phase, for all patients in all centres, except for Jordan, Saudi Arabia, Sudan 
and Yemen, where DOTS was not uniformly carried out for all patients [45].  
 
In all countries in this region, sputum smear microscopy was the basis of diagnosis of pulmonary 
tuberculosis and was provided free of charge at all diagnostic centres. According to [46], 18 countries 
reported a laboratory network coverage for direct smear microscopy within the recommended level of 
one laboratory per 50 000–250 000 of the population. All countries, except Djibouti and Somalia, 
reported having culture laboratories. External quality assessment for culture laboratories was reported 
to be 100 per cent in six countries. All countries in the area, except Djibouti, occupied Palestinian 
territory and Somalia, had drug susceptibility testing laboratories. 
 
2.7 TB CONTROL 
The control of TB depends on whether the transmission cycle can be interrupted by decreasing 
numbers of infectious cases by effective case-finding complemented by high cure rates [4]. By 
reducing the infectious period through prompt intervention with appropriate chemotherapy, it 
decreases the possibilities that members of the community continue to be exposed to infection [38]. 
Many strategies and intervention had been developed globally and sometimes contextualized to serve 
the national needs and fulfil these goals. Some adopted the global TB strategy and significant progress 
is being made on its implementation [46].  





2.7.1 The Stop TB strategy 
The Stop TB Strategy is the global TB strategy developed by WHO for the period 2006−2015 within 
the framework of the Millennium Development Goals (MDGs)[4]. The goal of this strategy is to 
achieve 2015 global targets for reduction in the burden of disease caused by TB. These targets can be 
translated to a reduction in the frequency of the disease, and that prevalence and mortality rates should 
be halved by 2015 compared to 1990 levels. The achievement of these targets will be discussed later 
under TB in MDGs. One of the major components of this strategy is pursuing high-quality DOTS 
expansion and enhancement. 
 
2.7.2 Directly Observed Treatment Strategy (DOTS) 
In 2009, coverage of DOTS in the region was reported to be 97 per cent [46]. Five countries did not 
achieve 100 per cent coverage: Iraq (87 per cent), Pakistan (99 per cent), occupied Palestinian 
territory (45 per cent), Sudan (91 per cent) and United Arab Emirates (20 per cent). The DOTS is a 
treatment intervention that focuses on the prompt treatment of symptomatic cases with short-course 
chemotherapy administered under direct observation of health providers [4]. The overall goal of this 
strategy is to reduce transmission of tuberculosis in the community through early detection of smear-
positive tuberculosis cases and rapid administration of the full-course treatment. The DOTS strategy 
demands political commitment, case detection by sputum smear microscopy and mostly occurs among 
self-referring symptomatic patients. A standard short-course chemotherapy is administered under the 
correct conditions including directly observed therapy, ensuring regular drug supplies and a standard 
recording and reporting system, which includes the evaluation of the treatment outcome [47].  
This goal translated into the detection of at least 70 per cent of estimated infectious cases and secured 
a treatment success rate of 85 per cent among detected cases by 2005 [48]. Disappointingly by the end 
of 2005, only 32 per cent of the estimated cases were detected through DOTS [48].  Currently, the 
DOTS strategy continues to struggle to resolve the problem of low detection rates by closing the gap 
between the number of notified cases and estimated incident cases [1]. The issue of low detection rate 
will be discussed in details later in this research.  In the MENA region, there was a significant decline 
in TB prevalence and TB-related mortality compared with a baseline in 1990, but the Millennium 
Development Goals (MDGs) targets were not reached [4]. 
 





2.7.3 TB in the MDGs 
The MDGs are the eight international development goals that were identified as reliable following the 
Millennium Summit of the United Nations in 2000. All 189 United Nations member states at the time, 
and at least 23 international organizations, committed to help achieve the Millennium Development 
Goals by 2015 [49]. TB was included as part of MDG 6 with targets that include five indicators that 
are TB incidence, TB mortality, TB prevalence, case detection rate for new cases and the treatment 
success rate for new TB cases [4]. The MDG target of the TB incidence rate falling by 2015 has been 
met worldwide in all six WHO regions (Table B2). The target to reduce TB mortality by 50 per cent 
has been met in three regions, Americas, South-East Asia and Western Pacific Regions. The African, 
Eastern Mediterranean and European Regions are unlikely to reach the target. The target of a 50 per 
cent reduction in TB prevalence has been achieved only in the Americas and the Western Pacific 
Regions and from the other regions only South East Asia Region appears on track to reach the target. 
The Targets for the treatment success rate among new TB cases and the case detection rate 
(notifications of new and relapse cases divided by estimated incidence) were not set for 2015. 
Treatment success rates were above 85 per cent globally in 2012 and the case detection rate was 64 
per cent in 2013 [4]. 
The United Nations Summit for the adoption of the post-2015 development agenda will take place in 
September 2015 in New York. The post-2015 development agenda includes the Sustainable 
Development Goals (SDGs) with targets set for 2030. One of these goals, ―Ensure healthy lives and 
promote well-being for all at all ages‖, includes a target to ―end the epidemics of AIDS, tuberculosis, 
malaria, and neglected tropical diseases and combat hepatitis, water-borne diseases, and other 
communicable diseases‖ by 2030.  
Table B2: Progress towards 2015 targets set within the MDG framework. Adapted from WHO 2014 
global TB report. 
MDG FRAMEWORK: INDICATORS AND TARGETS 







detection rate  
TB treatment 
success rate 








Not set Not set 
Global Met Not in track Not on track 64 (61–66) 86 
AFR  Met Not on track Not on track 52 (46–57) 81 
AMR Met  Met 77 (73–80) 76 




EMR Met Not on track Not on track 58 (49–71) 87 
EUR Met Not on track Not on track 80 (77–84) 75 
SEAR Met Not on track Met 62 (59–65) 88 
WPR Met Met  Met  83 (79–88) 92 
AFR; African, AMR; Americas, EMR; Eastern Mediterranean, EUR; European, SEAR; South-East Asia, WPR; 
Western Pacific On track means that the indicator will likely be achieved by the end of 2015 based on the current 
predicted trend. 
 
2.7.3.1 Post-2015 TB strategy 
Currently, the transition between the MDGs that established in 2000 and a post-2015 development 
framework are in progress. Within this framework, the WHO developed a post-2015 strategy that 
targets to end the global TB epidemic by 2035 [4]. Similarly,  global targets are a 95 per cent 
reduction in the number of TB deaths and a 90 per cent reduction in cases, compared with a baseline 
of 2015 [4] see Table B2. 
Table B2: the post-2015 TB strategy (adapted from WHO 2014 global report p. 19)  
VISION  A TB-free world 
 — Zero deaths, disease and suffering due to TB 
GOAL  End the global tuberculosis epidemic  
MILESTONES FOR 2025 — 75% reduction in TB deaths (compared with 2015) 
— 50% reduction in TB incidence rate (less than 55 TB cases per 100 000 population) 
— No affected families facing catastrophic costs due to TB 
TARGETS FOR 2035 — 95% reduction in TB deaths (compared with 2015) 
— 90% reduction in TB incidence rate (less than 10 TB cases per 100 000 population) 
— No affected families facing catastrophic costs due to TB 
PRINCIPLES 1. Government stewardship and accountability, with monitoring and evaluation 
2. Strong coalition with civil society organizations and communities 
3. Protection and promotion of human rights, ethics and equity 
4. Adaptation of the strategy and targets at country level, with global collaboration 
PILLARS 1- Integrated, patient-centred care and prevention 
2. Bold policies and supportive systems 
3. Intensified research and innovation 
2.8 TB INTERVENTIONS 
 
TB control can be categorized broadly into four major interventions: 




2.8.1 Treatment of Tuberculosis 
 
An intervention that focuses on two broad aims; firstly to reduce the risk of death and restore health 
and curing patients and secondly, to reduce the risk of transmission in the community [38]. Treatment 
intervention is the most widespread method for TB control and it has two main fundamentals parts, 
case finding and case holding [50]. For this to occur, it is essential to maintain a high suspicion index 
by health providers [51], timely initiation of proper treatment and increase patient‘s awareness and 
health worker‘s readiness to control the spread of TB. Social and cultural factors in the control 
process and their contribution must also be considered [47]. 
2.8.2 Active Case Finding and Treatment of Smear-Positive Tuberculosis 
 
The main objectives of this approach is to ensure early detection of active TB in order to reduce the 
risk of poor disease outcomes and the adverse social and economic sequences, as well as help to 
reduce the transmission of TB. However, this strategy requires a special effort by the health care 
system to increase the detection of TB in a given population.  
Broadly, there are two major means of active case finding. Mass mini radiography for population 
screening and population surveys using TB symptoms to screen patients (symptomatic screening) 
[52]. The mass radiography showed 90 per cent detection of active TB cases and 85 per cent of 
inactive TB cases. But, this needs huge investment and is extremely expensive. Symptomatic 
screenings are less costly to implement, but may detect only 70 per cent of prevalent cases, depending 
on the target groups and the methods used to elicit symptoms [52].  
 Active case finding are criticised in many debates and was abandoned in 1974 by WHO‘s Steering 
Committee in TB due to cost and that it frequently leads to poor treatment compliance [53]. 
Furthermore, active case finding is difficult on a large scale and requires the investment of extensive 
human and financial resources in identifying a relatively small number of cases. Also, there is no 
universal consensus on the impact of active case finding on TB incidence [54]. Many mathematical 
models have examined this relationship with the same conclusion. 
 
One of these models modelled active case-finding approaches after considering costs and prevalence 
in different regions of the world. The authors concluded that ACF strategies combined with DOTS 
would yield enormous benefits in areas with high TB prevalence, and many deaths could be prevented 
[54]. However, recently published cluster-randomized control trial (c-RCT) used ACF revealed 
contradictory results [55].  This c-RCT was undertaken with South African gold miners and aimed to 
interrupt TB transmission by means of mass symptomatic screening. In regards to TB incidence, the 
trial showed similar TB rates in the intervention and control clusters. The incidence of TB was 3.02 
per 100 person-years in the intervention cluster and 2.95 per 100 person-years in the control clusters 




and the authors concluded that mass screening had no significant effect on TB control in gold miners 
[55]. 
 
2.8.3 Preventive therapy 
         2.8.3.1 Preventive therapy for contacts of tuberculosis patients 
 
This intervention defined as preventative treatment that aims to prevent infection with TB bacilli from 
occurring through contact with TB patients and adults in the general population [38]. Success of this 
intervention must combine two elements that are the active tracing of contacts and prophylaxis 
treatment. In practice, contact investigation to identify recent infection has been limited to children 
within the household, which restricts the comprehensiveness of this intervention [47]. The usefulness 
of this intervention among the adult population with latent infection is also expected to have a 
protective efficacy of 60-80 per cent, depending on the duration of therapy [56]. The main limitations 
facing this intervention are partial uptake and compliance with prophylaxis agents [56].  
        2.8.3.2 Preventive therapy in people with HIV infection  
This intervention is defined as treatment of a sub-clinical, latent Mycobacterium tuberculosis 
populations in the human host and is given to reduce the risk of progression to clinically overt TB 
[38]. Preventive chemotherapy for six to twelve months using isoniazid is effective but operationally 
inefficient. In adults, there is the danger of mono-therapy of clinically active TB, which might not be 
recognized if mycobacterial culture facilities and chest radiography procedures are not routinely 
available [38]. This is of particular concern in HIV-infected patients who would be most likely to 
benefit because they frequently have active TB not identified on sputum smear microscopy alone 
[47,56]. Preventive chemotherapy is an individual intervention and does not appear to have as great an 
epidemiologic impact as chemotherapy for TB [38]. Even if precautions could be taken to prevent 
unintentional mono-therapy for patients with active TB, it remains an inefficient tool that reaches only 
a fraction of persons infected with M. tuberculosis [38].  
2.8.4 Vaccination with Bacilli Calmette-Guerin (BCG) 
Vaccinations aim at reducing the risk of progression from infection to disease. Consequently, its 
effect is expected to be similar to that of the strategy to reduce the prevalence of infection [38], but it 
is not considered to have a great epidemiological impact on TB transmission. The vaccine 
effectiveness is up to 80 per cent for disseminated TB, mainly TB meningitis in childhood, but not 
PTB in adolescents and adults [52].  




2.9 CERTAIN CHALLENGES TO TB CONTROL 
                        2.9.1 Limitations of Passive case finding  
 
Currently, the principal means of controlling transmission and reducing incidence in developing 
countries relies on the passive case finding approach [4].  This method is based on diagnosing 
infectious cases who present at the health facilities using sputum smear microscopy [57]. This type of 
case detection is effective in patients with pronounced symptoms but less effective in early diagnosis 
for people with less obvious symptoms.  
 
Another shortcoming of this approach is the difficulty in detection of patients with sputum-smear-
negative TB. This point is highly important, because as the numbers of undetected smear-negative 
PTB increase, their contribution to the total burden of TB and total transmission also increases. 
Consequently, this becomes one of the major forces driving the epidemic [58]. 
 
Passive case finding is influenced by factors such as patient motivation, the degree of diagnostic 
suspicion by health workers and the quality of laboratory facilities [59,60].  Therefore, it is considered 
to be a major source of delayed diagnosis discussed in detail in the following sections.  
 
                    2.9.2 Low TB Case detection rate  
 
A low detection rate of TB is one of the major difficulties confronting TB control worldwide. 
Globally, ―the number of TB cases diagnosed and notified per 100 000 population remained relatively 
stable between 1990 and 2000, rose sharply between 2000 and 2008, and subsequently slowly started 
to fall‖ [4]. In 2013, about 64 per cent of the estimated 9 million people with TB were notified as 
being newly diagnosed cases. This is estimated to have left about 3 million cases that were either: 
 
 Not diagnosed (due to poor access to health care and/or failure to detect cases when people 
visit health care facilities), or 
 Diagnosed, but not reported to national TB programmes, such as the failure of reporting cases 
diagnosed in the private sector (NTPs)[4].  
According to the World Bank, the TB Case Detection Rate (CDR) for ―all forms‖ of TB in the region 
was 70 per cent in 2013 (Figure B3) [44]. This rate varied across the countries in the region where 
some countries corresponded to higher rates such as in Turkey, Yemen, Tunisia and Morocco 88 per 
cent, 88 per cent, 87 per cent and 85 per cent respectively. The countries with very low rates are Iraq 
and UAE, 57 per cent and 50 per cent respectively. The remaining countries vary between 65 per cent 




and 73 per cent [44]. It must be noted that these CDRs are for all forms of TB, i.e. Pulmonary TB 
(PTB) both smear positive and negative, Extra-pulmonary TB (EPTB), relapse forms and etcetera. 
Regrettably, there is no recent data for CDRs in smear -positive TB in the region.  
 
The WHO 2008 report noted that, while the CDR for all forms is currently up to date, the NTPs in the 
region could detect on average one-third of smear-positive pulmonary TB cases. The remaining two-
thirds will thus continue to transmit TB infection in the community until identified by other health 
sectors [5]. This is very alarming because infectiousness is higher among smear positive PTB cases 
where the proportion of contacts found infected at the time of diagnosis of a smear-positive index case 
is between 30–40 per cent. If the case are not detected and adequate treatment provided, the circle of 
susceptible contacts will widen [5]. The delay of case detection is one of the major challenges and 
obstacles faced by NTPs in all areas and will be discussed further in this chapter.  
 
WHO developed two initiatives to solve the problem of low detection rate are the public-public and 
public-private mix (PPM) initiatives [4]. The involvement of all public, voluntary, corporate and 
private providers through PPM approaches is one of the chief components of TB strategy. Globally, 
many countries have implemented PPM initiatives and in most of these, PPM initiatives contributed 
about 10–40 per cent of total notifications.  
 In the MENA region, the NTPs started collaborating with key non-programme health care providers, 
including prison services, university hospitals, health insurance organizations, nongovernmental 
organizations and the private sector. The NTPs in Egypt and northern Sudan have identified or 
recruited a full-time individual in their central unit who is responsible for public-private mix-related 
issues. In Egypt, Islamic Republic of Iran, Jordan, southern Sudan and the Syrian Arab Republic the 
proportion of cases detected by non-programme providers constituted one-third or more of the total 
TB cases discovered. Whereas, in Iraq, northern Sudan and Yemen this proportion is less than 10 per 
cent [46]. 
These two problems (passive case finding and low case detection rate) contribute critically to the 
problem of delay diagnosis and initiation of treatment in TB and will be further discussed.   





Figure B3: shows the TB case detection in MENA between 1990 and 2013. The CDR increased by 
only 10% from that in 1990. Resource; World Bank available on 
https://www.quandl.com/data/WORLDBANK/MEA_SH_TBS_DTEC_ZS-Middle-East-North-Afric  
 





2. DELAY IN THE DIAGNOSIS AND TREATMENT OF TB 
 
Despite the advances and decentralizing of TB diagnosis and treatment, the pool of undetected TB 
cases still remains large in many countries. This is particularly among the high-risk groups such as 
those with HIV, close contacts of TB patients, miners, prisoners, intravenous drug users, homeless 
people and others [58]. The delays in detecting and diagnosing TB cases leads to higher risk of death, 
exacerbates the course of the disease and high financial consequences [58]. In addition, delayed 
diagnosis increases the duration of infectiousness, enhances transmission, especially in poor living 
and working conditions (overcrowding and inadequately ventilated environments), and expands the 
disease epidemic [5,58,61,62]. Furthermore, the patient becomes more contagious as the delay 
progresses, which can positively associate with the bacillary number in the sputum smear [39].  
Therefore, TB controls to stop disease transmission through early diagnosis and immediate initiation 
of treatment are vital and examining the reasons for delays in detection and treatment are significant 
for TB control programmes in improving their strategies. These delays may be attributed to patients 
and the health care system [57]. The patients may delay seeking help, or the health care system may 
delay in investigating for TB. Therefore, focusing on patient and health system factors associated with 
delays in detection of TB is important for identifying points of intervention for TB control [36,63,64].  
 
3.1 Consequences of TB Delay  
Several studies studied the consequences of delaying the diagnosis and treatment of TB [51,61,62,65-
67]. Their results can be summarized as: 
2.1.1 Community-related consequences  
Delay in the diagnosis and treatment, especially in active cases, enhances transmission within the 
community [5,38,57,68]. As mentioned earlier, the transmission of TB from an infectious person 
depends on three major factors. These factors concern the relationship between time and degree of 
infectiousness together with the number of available susceptible contacts and the time from onset of 
infectious disease to diagnosis [38]. Accordingly, the risk of becoming exposed is greater if the 
number of infectious cases increases and the duration of infectiousness is prolonged. Without 
treatment, a person with active PTB can infect on average 10 to 15 persons a year [69]. In particular, a 
study from California found that during the delay, patients exposed an average of eight contacts [62]. 




This would be higher in settings where there is problems related to overcrowding and higher social 
capital. Moreover, the study by Rao et al. (1999) found that management delays (from admission to 
treatment initiation) result in an average of 23.9 health care workers being exposed. As a 
consequence, the subsequent evaluation of each of these workers adds substantially to the overall 
costs of hospitalization [51]. 
 
2.1.2 Patient-related consequences  
Many studies [62,65-67] but not Rao et al. (1999) conclude that delay in the diagnosis and treatment 
exacerbates the course of the disease and increases the risk of death, especially where there is HIV co-
infection. A hospital based study conducted by Rao et al. (1999) in the United States found the delay 
to worsen the course of the disease but not related to TB mortality rates [51]. This contradiction could 
be attributed to the low incidence of HIV co-infection in the population studied by Rao et al. (1999) 
whereas, the rest of these studies were conducted in high HIV prevalence settings.  
 
Another patient related consequence is financial as patients spend more money on consultation either 
with health care providers or traditional healers, and buying non-effective/relevant treatment. Also, 
absenteeism from work due to illnesses might affect the needs of the patient‘s family.  
 
3.2 Levels of delay in the diagnosis and treatment of tuberculosis 
 
Most studies divide the pre-treatment period into two main time frames: a period before the patient 
presents to a health care provider and after the patient‘s first contact with a health provider until 
diagnosis and initiation of anti-TB treatment. 
 
3.2.1 Total diagnostic delay 
 
The total diagnostic delay is defined as the period related to both patient and health care provider 
before diagnosis and initiation of treatment [5]. There are many factors influences this delay period 
mainly the health seeking behaviour among the patient. Health seeking behaviour is very complicated 
process and governs by so many factors. Understanding of these factors could reduce delay to 
diagnosis, improve treatment compliance and improve health promotion strategies in a variety of 
contexts [70]. These factors have been examined under so many situations by deferent behavioural 
models from social psychology, medical sociology and medical anthropology [70]. One of these 
models is the Andersen‘s Behavioural Model of Health Care Utilization that initially developed in the 
late 1960. The model suggests that people‘s use of health services is a function of their predisposition 




to use services. In which, factors which enable or hinder use, and their need for care, providing a way 
to conceptualize these variations in utilization rates and consumption of medical resources [71]. In 
this model, use of health care services is a function of 3 main domains: need, enabling, and 
predisposing factors. Need factors, account for the majority of the explained variability in physician 
use, include the individual‘s perceived health care need and other indicators of their health status. 
Enabling factors include items such as the individual‘s income, health insurance status, and access to 
a source of regular care. Finally, predisposing factors include demographic variables, socioeconomic 
status, attitudes, and beliefs [71]. This categorization will be used in the next section when analysing 
the factors for TB delay. 
 
The length of total diagnostic delay varied with a range from 30 days in the Philippines [50] to 136 
days in Tanzania [72]. In most MENA‘ countries, the mean diagnostic delay ranged between one and 
a half months to four months [5]. The length of the diagnostic delay was 46 days in Iraq[5], 53 in 
Sudan[47] 57 in Egypt [5], 46 in Morocco [73], 59.2 in Yemen [5], 79.5 in Somalia [5], 77.6 in Syrian 
Arab Republic [74], 127 in Islamic Republic of Iran [5], and 78.5 in Turkey [25].  
 
 
3.2.2 Patients delay 
 
There is no obvious consensus regarding the definition of patient delay.  The WHO definition of 
patient delay is the time interval from the appearance of the major pulmonary symptoms of the 
disease until the first visit to a medical care centre [5]. There are some differences in the use of this 
definition that may be due to different descriptions of what is meant by the health system and who 
represents medical care and the TB symptoms. For example, a study conducted in New York defined 
patient delay as the period from the onset of any TB or non-TB symptoms to the first visit to a 
medical centre [75]. This definition was considered inaccurate according to the WHO as it defines the 
TB suspect case as any person who presents with symptoms or signs suggestive of TB. The most 
common symptom of PTB is a productive cough for more than two weeks, possibly accompanied by 
other respiratory symptoms (shortness of breath, chest pains, haemoptysis) and/or constitutional 
symptoms (loss of appetite, weight loss, fever, night sweats, and fatigue)[76].  
 
Another definition, applied in Gambia, was the period between the onset of pulmonary symptoms of 
TB and first consultation with any person which included traditional healers, market drug sellers, 
pharmacists, village health workers, friends and relatives as well as medical staff [77]. This yields the 
shortest delay ever documented (two days)[77]. Although different definitions for the patient delay 




seem ambiguous, these discrepancies enrich the outcome of studies conducted and made their 
conclusions more specific and focused [47]. 
 
The specific period to be considered as a patient delay likewise seems unclear. Some researcher 
considered 30, 45 or 60 days as a significant delay period while others choose their cut-off point 
based on physician‘s clinical practices and experience [78]. Patient delay is considered to be the main 
contributor to total delay in some studies [5,50,75,77,79-81]. This point is highly significant when 
detailing TB control interventions especially in resource-limited settings where the main focus should 
target this period more than the health system one. 
 
Numerous factors are identified as contributors to delay in seeking health services. One of the most 
important is the effect of stigmatisation of TB mediated denial and concealment of TB diagnosis, 
especially among women. Also, anxiety regarding high costs for diagnosis and treatment (perceived 
barriers) especially among men and that the standard of health facilities did not meet expectations of 
appropriate health services in terms of resources and staff competence [47]. There is a vicious circle 
of repeated consultations with a multitude of healthcare providers without a correct diagnosis that 
plays a major role in the delay in many countries [63].  
 
3.2.3 Health systems delay  
 
The gold standard definition of health system delay is considered as the time interval between the date 
of the first presentation of patients to a professional health provider and initiation of treatment [5]. 
However, different definitions were used in the literature by many researchers like ―the time interval 
from the first consultation until date of TB diagnosis‖ [82]. The shortcoming of this definition is 
obvious.  TB diagnosis, although an important component in TB control, is not the end goal of TB 
control programmes. Getting diagnosed is not a guarantee of starting and being treated. The time 
between being diagnosed and commencing treatment for some patients is very long [37].  
 
Another study used the definition of the time from the first visit to a health provider to diagnosis [77]. 
The author defined the health provider to be ―any person consulted by the patient about his/her 
sickness who gave or prescribed something (whatever the form) for treatment. These included 
traditional healers, market drug sellers, pharmacists, village health workers (VHWs), friends and 
relatives as well as medical staff‖.  This broad definition yielded the longest health system period ever 
documented (10.8 weeks)[77]. 
 




The lack of definitions to specify an accepted period of delay between TB diagnoses and start of 
treatments plays an important role in terms of what is considered as a health system delay. Some 
studies considered 7 days, others 10 days, 14 days, or based on physician‘s practices when the 
physician choose their delay cut-off point [78]. 
 
The shortest health system delay was documented in the USA with a mean period of 6 days [75]. The 
longest delay was documented in Gambia (10.8 weeks) [77]. Based on systematic review of 58 studies 
globally, the contribution of health provider‘s period in the total diagnostic delay was varied. As a 
result of using different definitions, studies stated that health provider delay was the main contributor 
to the total delay, but not in all studies [63]. For example, studies from Ethiopia, Gambia and Ghana 
[77,82,83] found that the health provider delay is the main contributor to the total diagnostic delay; 
these studies included part of patient‘s delay within the definition of health system delay. The study 
from the Gambia [77] assumed that traditional healers or family members could be health providers. 
In the Ethiopian study [82], a health provider was defined as anyone who gave the patient something 
as medication.  
 
The delay within the health system is influenced by several factors such as prevalence of TB, 
accessibility of health facilities, patient‘s socio-demographic characteristics, symptoms on 
presentation, presence of refined suspicion index, infrastructures and organization of the health 
system [47]. 
 
3.3.4 Certain factors associated with delay in TB diagnosis and treatment 
Rural and urban settings: Studies from Botswana [1], the Gambia [15], Tanzania [14], Ghana [22] 
and Korea [25], showed that the delay were significantly longer in rural areas. In Somalia, living in 
the suburbs and rural areas was associated with double the risk of delay compared to urban areas [5]. 
Age of the patient: TB represents a markedly aging epidemic, with a progressive increase in the 
notification rate with age and a peak among those aged ≥65 years old in the Eastern Mediterranean 
Region [4]. A review found 56/58 studies documented that older patients (>40 years) were at a much 
higher risk of TB diagnostic delay compared with those younger than 40 years [63]. According to a 
South African study, this can be attributed to coexisting medical conditions in the elderly persons, 
such as heart diseases and chronic chest problems, which may contribute to the difficulty of 
diagnosing TB, and can thus result in delayed diagnosis and treatment [84].  
Gender of the patient: In 2012, an estimated 33% of incident TB (2.9 million cases) occurred among 
women worldwide [85]. Although the global case notification rate of TB is lower for women than 




men, TB is among the top three (the other two being maternal related deaths and HIV) killers among 
women aged 15 to 44 years [86]. Diwan V one of the first researchers considering TB control as a 
gender issue [87], fortified a gender-based approach to TB control with the idea that would promote 
understanding biological variations, cultural differences, and even structural violence leading to 
poverty, inadequate health care resources and increased risk of tuberculosis and death [87]. 
Sociocultural structures are the main gender-specific barriers to accessing TB diagnostic and 
treatment services [88]. This review emphasized that women experienced barriers due to financial 
dependence, lack of physical independence, the de-prioritization of their health in households, stigma 
within the household, relatively low general and TB-related literacy, and the expectation that an ill 
wife must take care of her husband, but not vice versa [88]. On the other hand, men primarily 
experienced community-based stigma and work-related financial and physical barriers, which reflect 
their higher status/power and role as the primary earner [88]. In addition, gender-specific issues seem 
to impact marriage due to TB related stigma. For men diagnosed with TB, the potential inability to 
work and support the family appeared to be linked to reduced marriage likelihood [88]. Whereas 
women, diagnosed with TB, found to be faced with concerns regarding fertility before marriage, 
threats of divorce after marriage due to fear of contagion and the inability to perform household 
chores [88].  
HIV status: In the MENA region, there are only 2% of the global estimated number of people living 
with HIV [31]. However recent estimates show that it is one of the two regions with the fastest 
growing HIV epidemics. Insufficient commitment, stigma, discrimination, and inappropriate laws 
continue to obstruct work with people living with HIV and people on the margins in the MENA 
region. Hence rapid actions to curb demand exceeding supply are highly recommended [31]. 
HIV/AIDS among tuberculosis (TB) patients is a useful indicator of the maturity of the HIV epidemic 
in a given setting because it reflects the presence of advanced HIV or AIDS cases in the population 
[33]. TB considered a leading cause in death of HIV infected patients and accounting for 25% of HIV 
related death [1,3,4,34]. The mortality rate and the incident rate of new AIDS-defining opportunistic 
infections were founded to be higher for HIV-TB-co-infected patients than for HIV-infected patients 
without active TB who were matched for CD4 cell counts [35].  
The relative risk of TB doubles in the first year after HIV infection, when CD4 counts are still 
preserved, and continues to increase during the years after seroconversion as CD4 counts decrease 
[35]. HIV increases the risk of progression to active TB in both primary TB infection and the 
reactivation of latent TB [35]. The sub-optimal performance of traditional TB diagnostic tools, such 
as smear microscopy and chest X-ray (CXR), in HIV co-infected patients had led to relying on other 
laboratory methods such as culture.   Culture however,  has a lag time-to result of up to 6 weeks, thus 
creating a diagnostic delay and increased morbidity and transmission [35].  




These are not the only factors that create diagnostic delay of TB among HIV patients.   A South 
African study found that older patients with elevated viral load and on ART while diagnosed with 
PTB are at higher risk of TB diagnosis delay [84]. Another study from Peru, found that the principal 
reasons for treatment-seeking delays were lack of knowledge and confusion of TB symptoms, fear 
and embarrassment of receiving a TB diagnosis, and a patient tendency to self-medicate prior to 
seeking formal medical attention [89]. The median delay was 55 days (IQR = 20 – 302) in South 
Africa [84], 73 days in Mexico [90], and 41 days in Brazil [91]. 
The main interventions to reduce the burden of HIV in TB patients are HIV testing and provision of 
ART and CPT to those found to be HIV-infected [1]. The main interventions to reduce TB among 
people living with HIV are regular screening for TB and provision of isoniazid preventive therapy 
(IPT) to those without active TB  who meet eligibility criteria [1].  
Stigma: Stigma widely affects both genders and was reported as a major barrier to accessing TB 
diagnostic and treatment facilities. Several, especially qualitative, studies describe the effects of 
stigma and discrimination associated with TB.  Social isolation of patients inside a family bond, 
where the patient may be forced to eat and sleep separately, or in the community, where the person 
may be avoided by former friends and acquaintances, was described as the main contributing factors 
to the stigmatization of TB patients in developing countries [92]. Patients often isolate themselves to 
avoid infecting others and to avoid uncomfortable situations such as being shunned or becoming the 
subject of gossip [92]. Communal lack of knowledge regarding TB transmission and the worry that 
TB is incurable or can be passed down to offspring lead to stigma that impasses the marital prospects 
of all TB patients, regardless of gender [88]. And it seems that stigma and health literacy are related. 
A higher degree of stigma was recorded in females compared to males in almost all MENA countries 
[5]. Concurrently, females were found to be at a significantly lower socioeconomic status and had 
poorer knowledge about TB compared to males in the region [5].In Yemen, Somalia, Syrian Arab 
Republic and Egypt, around 30%–40% of patients reported feeling ashamed of the diagnosis, and one 
quarter had to hide the diagnosis [5]. One quarter to 40% of patients agreed that tuberculosis affected 
social and marital relations, family responsibilities and work performance [5].  
Education and Knowledge about TB: Patients who had limited knowledge about TB were more 
likely to delay seeking care. Many studies found strong association between knowledge and level of 
education. for example in  Iraq the 64% of TB patients who had completed more than 9 years of 
education,  had a satisfactory level of TB knowledge [5].   In contrast the level of  TB knowledge 
found to be less than 30% in Tanzania with the majority of the patients having less than 9 years of 
education [72]. The percentage of patients in MENA countries with adequate TB knowledge , appears 
very low [5]. The source of this knowledge was found to be either friends of the patients, relatives or 




fellow tuberculosis patients.  However, in Egypt the media played a significant role where the main 
source of information about TB was documentary presentations by health staff of chest facilities [5]. 
Presenting symptoms: Atypical presentations of TB such as absence of cough together with negative 
sputum, extra-pulmonary TB, and absence of haemoptysis were associated with longer health system 
delay in USA, St. Louis, Missouri, Ghana, Ethiopia and Canada [51,61,75,83,93,]. Similarly failure to 
perform sputum examination, not having a chest radiograph at the first medical visit was associated 
with longer health system delay [51,61]. 
The vicious circle of repeated visits at the same level: Storla et al stated that approximately all the 
studies identified the problem of vicious circle of repeated consultations with a multitude of 
healthcare providers without a correct diagnosis as a major factor for delay [63].  
Three groups of healthcare providers were particularly identified as sources of this vicious circle: 
1) Primary-level government health posts, which have limited diagnostic facilities and poorly 
trained staff 
2) Private practitioners with low awareness of TB and, 
3) Unqualified vendors, quacks and traditional healers [63]. 
 
 Self-medication: Patients who start the process of health seeking by visiting non-formal healthcare 
services or practicing self-medication had a longer delay for the diagnosis of TB,  compared with 
those who initially seek formal healthcare services [82]. Study carried out in Thailand, highlighting 
the effect of the use of pharmacies on the delay in the diagnosis of TB. Had found that nearly 50% of 
patients had visited the pharmacy immediately after their onset of symptoms, while 12% of these 
patient who could recall details of this visit, indicated that the medication recommended was cough 
suppressants, mucolytic, bronchodilators and antibiotics, however, none were refer to a tuberculosis 
unit [94]. More than 94% of patients in Burkina Faso [63], about 50% in Pakistan [5] and 13% in Iraq 












Despite the MENA region having only 6% of the world‘s TB, several indicators such as overgrowing 
population, weak and devastating health systems as well as political and security instability in the 
MENA region might create opportunity for massive spreading of TB.   Thus, there is a need for a 
comprehensive review of factors which may play a role in the spread of TB within this region.  It is 
anticipated that this study, using rigorous methods of the systematic review process, will present a 
foundation towards efforts in containing the disease while, learning from other region‘s experience, so 
as to achieve satisfactory results in the MENA region.
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Background: The goal of Tuberculosis control is to stop disease transmission, thereby reducing 
mortality and morbidity rates. Early case detection and proper treatment will reduce the time of 
infectiousness in the community and hence the number of new individuals exposed and infected. Most 
transmissions occur between the onset of cough and initiation of treatment. Delay in case detection 
which eventually cause delay in diagnosis and treatment, may worsen the disease, increase the risk of 
death and enhance tuberculosis transmission in the community.  Currently, there exists no 
comprehensive review of factors playing a role in the delay of diagnosis and treatment for pulmonary 
TB in the Middle East and North Africa regions (MENA). 
Methods: we conducted a comprehensive literature search among the following databases,Cochrane 
Central Register of Controlled Trials (CENTRAL), Web of Science, PubMed, CINAHL, Psychlnfo, 
Scopus, Index Medicus for the Eastern Mediterranean Region (IMEMR), (Africa-wide) allied health 
and Google scholar of original data from MENA‘s countries on patient or health system delay in TB 
diagnosis or treatment. Electronic searches were complemented by a hand search for reference lists of 
potentially included studies.  Data were extracted, reviewed and rated using a single form by two 
reviewers independently. The quality of each study assessed in terms internal and external validity 
generalizability of the study results. We categorized patient and health system-related factors based on 
the predisposing, enabling or need as suggested by Anderson‘s behavioural model. Meta-analysis was 
conducted and subgroups were analysed according to the individual factors related to patient and 
health system delay.  
Result: Our initial search yielded 303 articles from nine databases, from which 20 studies were 
identified as eligible. Fifteen assessed both patient and health system sources of delay, 4 Studies 
assessed patient delay only and 2 studies assessed total delay without demarcation between patient 
and health system delay. Eighteen of our included studies were cross-sectional and used consecutive 
patient sampling. Eleven studies had a low risk of bias, seven studies had a moderate risk of bias and 
five studies had a high risk of bias. Due to shortcomings on the quality of evidence on the 
observational studies the GRADE system produced a low quality of evidence for this review.  
In all the studies, standard definition for patient delay was consistent; but not for health system delay 
where definitions varied considerably. Almost all the studies associated socio-demographic 
characteristics of the patients such as female gender and poverty with patient delay. Meta-analysis 
revealed that older age and low patient income were significantly associated with patient delay (OR, 
1.49; 95% CI, 1.31 to 1.70) and (OR, 1.26; 95% CI, 1.09 to 1.45) respectively. Adequate TB 
knowledge, high TB perception, employment and a low crowding index were protective factors from 




patient delay (OR, 0.72; 95% CI, 0.61 to 0.85), (OR, 0.60; 95% CI, 0.46 to 0.78), (OR, 0.83; 95% CI, 
0.72 to 0.95) and (OR, 0.78; 95% CI, 0.64 to 0.94) respectively. Visiting a public facility first was the 
only enabling factor to be significantly inversely associated with patient delay in meta-analysis. 
Female gender was significantly associated with both patient and health system delay in the MENA 
region (OR, 1.24; 95% CI, 1.02 to 1.50), and (OR, 1.68; 95% CI, 1.18 to 2.38) respectively. HIV/TB 
co-burden and needs factors were rarely assessed. 
Discussion: TB control programmes in the MENA region need to increase their efforts to reduce 
patient and health system delays in order to achieve their goals successfully. These findings highlight 
the necessity to raise the awareness about TB in the community and to build a good referral system 
and to develop interventions that understand the gender differences in the region. Research should lay 
emphasis on HIV and health system related factors and cohort studies to identify enabling and needs 
factors related to delay. 
 
Keywords: Tuberculosis case finding, Delayed Diagnosis, tuberculosis control, Middle East and 
North Africa, health care–seeking behaviour, delivery of health care. 







1.1 Description of the condition 
 
Tuberculosis (TB) remains a major global health problem as an estimated 9.0 million people 
developed TB and 1.5 million died from the disease in 2013 [1]. Despite the advances in and 
decentralizing of TB diagnosis and treatment, the detection of TB cases has never reached its 
expected potential in many countries. For instance, in 2013, about 64 per cent of the estimated 9 
million people who developed TB were identified as newly diagnosed cases. This is estimated to have 
left about 3 million cases that were either not detected, or not reported to national TB programs 
(NTPs)[1].  
In almost all of the Middle East and North Africa (MENA) the problem of delayed detection is a 
major challenge confronting TB control in the region. As a result of these delays, the infected patient 
has a higher risk of death, exacerbation of the course of the disease and, terrible social and financial 
consequences.  Moreover, this patient may increase the disease transmission within the community by 
infecting all his/her susceptible contacts. In particular, a study from California found that a delay of 
two months is enough to spread the disease to an average of eight contacts (2). This number will 
increase as delay progresses to reach 15 persons a year [1] and would be higher in settings of 
overcrowding and higher social capital. Moreover, the study by Rao et al.1999 [3] found that 
management delays (from admission to treatment initiation) will result in an average of 23.9 health 
care worker exposures. Thus, as the delay progresses, the epidemic is prolonged and expands. 
Therefore, to curb this and reduce poor disease outcome and adverse social and economic 
consequences, timely diagnosis and prompt initiation of anti-TB treatment is vital [4].  
 
 The most fitting approach to timely diagnosis is the active case finding which is based on mass 
screening for TB in a given population [4]. However, this approach is difficult on a large scale and 
requires a special effort by the health care system, such as investing extensive human and financial 
resources. This is the reason that all national TB programs (NTPs) currently rely on the passive case 
finding approach as the principal means of controlling transmission and reducing incidence in 
developing countries [1]. This approach is based on diagnosing infectious cases that present 
themselves to the health facilities using mostly sputum smear microscopy. Passive case finding by 
default is considered to be a major source of delayed diagnosis. 





Reasons for delayed diagnoses can be attributed to patients as well as to the health care system [5]. 
The patients may delay in seeking help, or the health care system may delay in suspecting and 
investigating for TB. These two periods are influenced by numerous factors (see figure C1) such as 
socio-demographic characteristics, stigmatization effect of TB, fear of high individual expenses, 
symptoms on presentation, presence of refined suspicion index, infrastructures and organization of the 
health system. Therefore, Focusing on patient and health system factors associated with delays in 






Figure C1: Conceptual framework (adapted form Yang et al.(2014)[11]) illustrating factors 
associated with patient and health system delay of TB diagnosis and initiation of treatment and TB 
care continuum from symptom onset to treatment initiation that were used to define delays that 
provides obstacles to TB control at the patient and health system level. Predisposing factors are 
factors that influence the initial performance of the behaviour. Enabling factors are those factors that 
make it possible or easier for individuals to enact the behaviour. Need factors are those factors that 
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1.2 Why is it important to do this review? 
 
Identification of the factors associated with TB delay has helped many regions to undertake measures 
to increase the effectiveness of their TB control programs;  for instance, in 1994 the Centre for 
Disease Control (CDC) in the United States issued guidelines for preventing the transmission of TB in 
response to studies published on the issue of delay [9]. Implementation of these guidelines resulted in 
reversing the upsurge in reported cases of TB disease and a decline in case rates in the subsequent 10 
years [9].  Through this review, we would like to instigate parallel results with regards to the MENA 
region. 
There are four previous systematic reviews that have addressed the delay of TB diagnosis and 
treatment, however, none focused on the MENA region [6,7,10,11]. The systematic review by 
Thomas 2002 [10] and Storla 2007 [7] includes antiquated studies not applicable to current 
functioning NTPs. Finnie (2011) analysed factors associated with TB delay in high HIV/ TB co-
burden areas in sub-Saharan Africa [6]. However, his review is not applicable to regions with a low 
HIV problem (i.e. MENA). Yang et al. (2014) included few studies from the MENA region, but their 
review was aimed at the gender differences in TB delay [11].  
In the MENA region, several factors contribute to devastating the health system in general and TB-
related services in particular. For instance, political instability contributes to emergency situations (the 
sectarian war and Arab spring) and economic sanctions have stretched resources beyond the systems‘ 
ability to cope, quality has deteriorated and many services defined as ―below standard‖ [12].  
In this study, the aim is to review systematically, all primary quantitative studies from countries in the 
MENA region which address factors associated with the delay in TB diagnosis and initiation of 
treatment. It is anticipated that this review will provide evidence for new or improved policies that 
incorporate an understanding of the current political situation, health system weakness and 












2.1 Primary Objectives 
 
 To study factors associated with patient and health system delay for diagnosis and initiation 
of treatment of pulmonary tuberculosis in Middle East and North Africa (MENA). 
 
 2.2 Secondary Objectives 
 To determine the magnitudes and contributions of patient period in the total pre-treatment 
period. 
 To determine the magnitudes and contributions of health system period in the total pre-
treatment period. 
 To determine the magnitudes of total delay. 







This review protocol has been published in the PROSPERO International Prospective Register of 
systematic reviews (http://www.crd.york.ac.uk/PROSPERO), registration number CRD42015023337 
3.1 Criteria for considering studies for this review  
  
 3.1.1 Types of studies 
Observational studies: case control studies, cross sectional studies and population based studies.  
In case of Randomized control trials (RCTs), cluster-randomized control trials (cRCTs), controlled 
before-and-after studies (CBAs) and cohort studies (prospective and retrospective) studies, we only 
used baseline population data. 
3.1.2 Type of Participants 
TB patients (or suspected TB patients) defined as: 
1- All chest symptomatic individuals with cough ≥2 weeks and suspected for TB, 
2- Pulmonary TB (PTB) patients (smear-negative, new smear positive or re-treatment patients),  
3- Pulmonary and extra-pulmonary TB (EPTB) (if data were presented for PTB separately). 
 
3.1.3 Types of outcome measures 
       3.1.3.1 Primary outcome   
     
                 1- Factors associated with patient and health system delay. 
       3.1.3.2 Secondary outcome 
              The magnitude of: 
 
1. Patient delay, defined as the time interval from onset of TB symptoms to first visit to any 
health provider.  
2. Health system delay, defined as the time interval from the first health provider visit to 
initiation of treatment. 




3.  Total delay is the time interval from the appearance of major of TB symptoms to initiation of 
treatment. 
3.2 Search methods for identification of studies 
 
A comprehensive search to identify both published and unpublished articles with the relevant studies 
with no language and time limit has been performed. The electronic searches were conducted on 
publications dating up to June 2015. We developed our search strategy for MEDLINE using PubMed 
with a combination of the following keywords: TB, tuberculosis,  mycobacterium, patient delay, 
health seeking delay, care-seeking delay, health system delay, doctor delay, health facility delay, 
health provider delay, diagnostic delay, diagnosis delay, total delay, detection delay, identification 
delay and treatment delay,   
A search for factors using key terms (factors or enablers and barriers) did not add any new articles and 
was hence taken out of the final search strategy. The search strategies incorporated both medical 
subject headings (MeSH) and free-text terms and adapted to suit each individual database using 
applicable controlled vocabulary. In addition, we looked over the reference lists of identified studies 
for additional studies. The complete strategy is shown in Appendix 1.  
 
3.3 Electronic searches 
The electronic searches were carried out on the following databases; Cochrane Central Register of 
Controlled Trials (CENTRAL), Web of Science, PubMed, CINAHL, Psychlnfo, Scopus. Grey 
literatures were searched in the Index Medicus for the Eastern Mediterranean Region (IMEMR), 
(Africa-wide) allied health and Google scholar. 
 





3.4. DATA COLLECTION AND ANALYSIS 
 
3.4.1 Selection of studies 
 
Two authors screened all titles and abstracts of identified references from the searched databases to 
select potential eligible studies. Thereafter, the full texts of potentially eligible studies were obtained 
and the final selection for inclusion into the review was conducted by two independent authors (DE 
and EP). Any disagreements regarding inclusion of studies was resolved by discussion and any 
conflicts were resolved by a third reviewer (ME).  
 
3.4.2 Data extraction and management 
 
Data were extracted from selected studies independently by two authors using standardized data 
extraction forms (see Appendix 2). Disagreements on study selection and data extraction were 
resolved by consensus between the two review authors, failing of which a third author was arbitrated. 
The extracted data were entered into a spread sheet for final analysis. The following descriptive and 
outcome data were extracted from each study: 
 Study identification details: authors, year of publication and relevance of cited references. 
 Study characteristics: study design, study setting, study participants, method of obtaining the 
study sample, country and sample size. 
 Details of our primary outcome measure: factors/variables assessed for association with 
patient‘ delay and health‘ system delay. 
 Details of our secondary outcome measure: the magnitude of patient, health system and total 
delay. Also the definitions used for patient, health system and total delay. 
 
 3.4.3 Assessment of risk of bias in included studies 
 
Risk of bias, was independently evaluated by two reviewers (DE & EP). Any disagreement was 
resolved by discussion, with arbitration by a third reviewer (ME) where necessary.  At data extraction 
phase we noticed that the majority of our included studies (n-12) construct their study‘s design into 
two design phases. The beginning phase (descriptive phase) which is a cross-sectional design to 
determine the extent of the delay, and then the second phase (analysis phase) in which a nested case–
control design were carried out comparing patients delaying above and below the median time. For 




this reason we choose to assess the quality of these studies according to their second phase or analysis 
phase i.e. we treated these studies as case-control studies. Therefore, the Newcastle - Ottawa Quality 
Assessment Scale (NOS) for case-control studies has been used to assess the risk of bias in these 
studies [13]. NOS tool are star system based on three domains: 1) Selection of Study Groups, 2) 
Comparability of Groups and 3) Ascertainment of exposure. This system identifies ‗high‘ quality 
choices with a ‗star‘ in which a maximum of one ‗star‘ for each item within the ‗Selection‘ and 
‗Exposure/Outcome‘ domains and maximum of two ‗stars‘ for ‗Comparability‘ domain. The 
thresholds score distinguishing between ‗good‘ and ‗poor‘ quality studies is 5 see table C1. 
 
For the rest of our included studies which were cross-sectional and descriptive surveys, we employed 
the quality assessment tool by Hoy et al. 2012 [14] that were adapted by Werfalli and colleagues 
which allows for a composite score to assist with relative comparison between the studies [15]. 
Werfalli and colleagues added a quantitative scoring system to the Risk of Bias allocating four points 
for external validly scores and six points for internal validity see supplementary materials 2. The 
scoring system tool categorizes high risk studies as those with an overall score of 0-5 points moderate 








































































































































































































































































































































































































































































































































































































































































































































































Table C: Quality assessment tool for cross-sectional studies [14] modified by [15]  
Items  Quality 
Score 
External Validity (4 points) 
1. Was the study's target population a close representation of the national population in relation to 
relevant variables? 
(1 point) 
2. Was the sampling frame a true or close representation of the target population?  (1 point) 
3. Was some form of random selection used to select the sample, OR was a census undertaken?  (1 point) 
4. Was the likelihood of nonresponse bias minimal?  (1 point) 
 
Internal Validity (6 points) 
1. Were data collected directly from the subjects (as opposed to a proxy)?  (1 point) 
2. Was an acceptable case definition used in the study?  (1 point) 
3. Was the study instrument that measured the parameter of interest shown to have validity and 
reliability?  
(1 point) 
4. Was the same mode of data collection used for all subjects?  (1 point) 
5. Was the length of the shortest prevalence period for the parameter of interest appropriate?  (1 point) 





0-5 points  Low Risk: Further research is very unlikely to change our confidence in the estimate 
6-8 points  Moderate Risk: Further research is likely to have an important impact on our confidence in the 
estimate and may change the estimate 
>8 points  High Risk: Further research is very likely to have an important impact on our confidence in the 
estimate and is likely to change the estimate. 
 
3.4.4 Data analysis and synthesis: 
We expressed the result of each study as an odd ratio with its corresponding 95% confidence interval 
for dichotomous data. We group studies that compare broadly similar types of outcome to get feasible 
results on an overall estimate of effect. Random effects meta-analysis was used due to anticipated 
heterogeneity in study results. Prevalence of TB delay from different studies was pooled in a meta-
analysis using Review Manager 5.3. 
 
3.4.5 Assessment of heterogeneity and subgroup analysis. 
 
We examined statistical heterogeneity between study results using the Chi-squared test of 
homogeneity (with significance defined at the alpha-level of 10%), and quantify any statistical 
heterogeneity between study results using the I-squared statistic [16]. For subgroup analysis, we used 
the Chi2 test for subgroup differences to test for subgroup interactions. 
3.5. Ethics 
 
Systematic reviews draw on publicly available secondary data and, therefore do not require formal 
ethical review [17]. It is noted that ethical research, even if secondary research, relies on scientific 
validity. The study protocol was reviewed by supervisors with expertise in systematic review methods 




and submitted to the University of Cape Town‘s Faculty of Health Sciences Human Research Ethics 




We did not receive any funding for this study. 






4.1. Study flow and description of studies 
 
The literature search results are reported according to the Preferred Reporting Items for Systematic 
reviews and Meta-Analyses (PRISMA) Statement [18]. 
 
We obtained 303 titles and abstracts from electronic databases and trial registries. We found 20 
additional articles through a hand search of the reference lists and one article by contacting relevant 
authors in the field. In total, we considered 266 articles after removing 58 duplicates. From these, 234 
articles were excluded after examining titles and abstracts leaving 32 articles requiring full-text 
evaluation.  From these, 12 articles were deemed unsuitable for the following reasons: participants not 
meeting inclusion criteria [19,20], participants were not from the MENA region [21][22] and, the 
outcome measure was not TB delay [23-30].  A total of 20 articles met our inclusion criteria. Figure 
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4.1.1 CHARACTERISTICS OF INCLUDED STUDIES 
 
 
We included 20 observational studies. Six were conducted in Iran [31-36], five  in Turkey [37-41], 
two in Yemen [42,43], two in Syria [44,45], two in Sudan [46,47], one in Jordon [48], one in Morocco 
[49] and one was a multicounty study conducted in seven countries in which Iran, Iraq, Egypt, Syria, 
Somalia and Yemen [50] were included. The majority of the studies (18/20) were cross-sectional in 
study design and two were nested case-control studies. The study participants were new smear 
positive PTB patients in 15 studies, TB suspects in one study [48] while four studies included both 
smear negative and smear positive PTB [39]. Fifteen assessed both sources of delay, four studies 
assessed patient delay only and two studies assessed total delay without demarcation between patient 
and health system delay.  Almost all studies used a consecutive method of sampling with sample size 
ranging from 50-5,702 that looked at least on one of the outcomes. Publication dates were between 
2001 and 2015.  In all studies, male was the dominant gender and majority of the studies were 
conducted in both urban and rural settings.  The characteristics and descriptions of the included 













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.2 Assessment of risk of bias in included studies 
The NOS criteria for case control study design and the quality assessment tool by Hoy et al. 2012 [14] 
that were adapted by Werfalli and colleagues [15] for cross-sectional study design that were adopted 
to assess the risk of bias in included studies is enclosed in the data extraction form in appendix 2. 
Eleven studies had a low risk of bias  [37,42,45-50], while seven studies had a moderate risk of bias  
[32,33,36,38-40,44] and five studies had a high risk of bias [31,34,35,41,43]. Table C4 and C5 depicts 
a summary of the assessment of risk of bias of each study.  
NOS criteria: The majority of our studies (n=8) had a full score of the ―selection of participants‖ 
criteria that composed of four subcomponents (A1 right case definition, A2 right controls definition, 
A3 the representativeness of the cases, A4 the representativeness of controls). In this criterion the 
right case definition means either confirmed PTB case or suspect PTB case not seeking healthcare for 
more than the cutoff value used by each study. Whereas the right controls definition refer to either 
confirmed PTB case or suspect PTB case not seeking healthcare for less than the cutoff value used by 
each study. The second criterion is the ―comparability of the groups‖ composed of two subcomponent 
(B1 control of main confounders, B2 control of any additional factor). Eight out of the twelfth studies 
had adjusted for the several confounders such as age, sex, income, employment status, education and 
others. The third criterion is ―ascertainment of the exposure‖ that composed of three subcomponent; 
(C1 appropriate method of exposure ascertainment, C2 same method of exposure ascertainment for 
cases and controls, C3 same non-response rate of case and control groups). The measures of patient 
delay in all included studies were dependent on patient recall of first symptoms for PTB, and then 
these studies might be exposed to recall bias. However, attempts had been taken to minimize 
problems of recall in Rahim 2004 by excluding any new smear-positive case with treatment duration 
of more than 5 weeks. All the studies scored full for C2 and C3 since both patients and controls 
treated similar in data collection. 
Hoy criteria: This criterion has two domain external validity and internal validity. We found that 
majority of studies were not externally valid in spite of being internally valid. With regard to external 
validity, failure to have representative sample and/or minimal non-response bias were the main issues 
that hinder [32,34-36,38,40] from being externally valid. Whereas failure to collect the information 
directly from the participant in [36,34] and non-reliable and non-valid study‘ measures in [32,34-
36,38,40] were the main issues that hinder these studies from being internally valid. Almost all the 
studies (n=8) succeeded to have acceptable case definition in which these studies was follow WHO 
definition for TB case. Eight out of ten studies collected data directly from the subject as opposed to a 
proxy by using same mode of data collection.  Some studies such as [32,33,44,39] didn‘t provide 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.3 QUANTITATIVE DATA SYNTHESIS. 
Main results of included studies 
 
4.3.1 Patient delay  
 
From the 20 included studies, 17 studies measured the patient delay. Measures of patient delay depend 
on patient recall of first symptoms for PTB. In the entire studies first symptom was described as the 
onset of a persistent cough as the starting point and date of first consultation as endpoint. The majority 
of the studies measured delay as a dichotomous variable based on a cut-off point, usually the median. 
The shortest mean duration of patient delay (12.5 days) reported in Iran by Masjidi et al. 2002 [32], 
whereas, the longest mean duration (73 days) reported also in Iran by Shahriyar et al. 2012 [35]. The 
time period of the research was reported by all the studies. When we plotted the patient period 
according to the year of study not the year of publication (figure C2), the plot shows no reduction in 
patient delay over time. In fact in some countries such as in Iran, we observe that the delay increases 
dramatically overtime. However the quality of these studies should be considered before setting any 
conclusion about this observation.  
 
 
Figure C3: time trend of mean patient delay with studies ordered chronologically, 
 
4.3.2 Analysis of patient delay by subgroup  
A.1 Factors associated with patient delay 
 
Out of 17 studies that measure the length of patient delay, only 10 studies analysed at least one factor 
attributed to this period [31,37,42,43,45-50a]. Each factor was classified as a predisposing, enabling 
or need factor as suggested by Andersen‘s behavioural model of health care utilization [51]; 




Predisposing factors are factors that influence the initial performance of the behaviour. Enabling 
factors are those factors that make it possible for individuals to enact the behaviour. Need factors are 
those factors that follow enactment of behaviour and influence continuation. Studies mostly assessed 
the predisposing factors such as patient socio-demographic characteristics, TB knowledge and 
perception about TB. The enabling factors were less assessed, while no studies found to be assessed at 
least one ―ned‖ factor. Table C2 and figure C2-10 give further details on the findings pertaining to 
factors associated with patient delay.  
 
A1.1 Predisposing factors to patient delay 
 
A1.1.1 Gender  
Female gender was significantly associated with patient delay (OR, 1.24; 95% CI, 1.02 to 1.50), 10 
studies contributed to summary odd ratio [31,37,42,43,45-50a]. Heterogeneity was significant (P <0.1; 
I² = 45%). 
 
 
Figure C4: Forest plot, Gender vs. patient delay. 
 
A1.1.2. Age  
Older age was significantly associated with patient delay (OR, 1.42; 95% CI, 1.19 to 1.69), nine 
studies contributed to summary odd ratio  [31,37,42,45-50a]. Heterogeneity was insignificant (P 
=0.18; I² = 31%). 





Figure C5: Forest plot, Age vs. patient delay. 
 
A1.1.3. Employment  
 
Employment was significantly inversely associated with patient delay (OR, 0.83; 95% CI, 0.72 to 
0.95), five studies contributed to summary odd ratio [42,45,46,48,50a]. Heterogeneity was 
insignificant (H, p=0.65; I² = 0%) 
 Figure C6: Forest plot, Employment vs. patient delay. 
 
A1.1.4. Patient’s income 
 
Low patient‘s income was significantly associated with patient delay (OR, 1.95; 95% CI, 1.07 to 
3.55), seven studies contributed to summary odd ratio [37,42,45-48,50a]. Heterogeneity was 
significant (P <0.00001; I² = 92%). 
 




 Figure C7: Forest plot, Patient’s income vs. patient delay. 
A1.1.5. Crowding   
 
Low crowding was significantly inversely associated with patient delay (OR, 0.75; 95% CI, 0.57 to 
0.99), three studies contributed to summary odd ratio [42,45,50a]. Heterogeneity was insignificant (P= 
0.15; I² = 47%): 
 Figure C8; Forest plot, crowding index vs. patient delay. 
 
A1.1.6. TB knowledge 
Six studies assessed TB knowledge as predisposing factor to patient delay [42,45,47-50a]. In which, 
only two studies [42,50a] found the association between adequate TB knowledge to be significant 
with patient delay (OR, 0.28; 95% CI, 0.20 to 0.41) and (OR, 0.60; 95% CI, 0.39 to 0.93) 
respectively.  
A1.1.7. TB perception  
Four studies assessed TB perception as predisposing factor to patient delay [43,46-48]. While one 
study [47] found high TB perception to be significantly associated with patient delay (OR, 2.38; 95% 
CI, 1.25 to 4.54), other two studies [43,48] found high TB perception to be protective from delay (OR, 
0.27; 95% CI, 0.10 to 0.74) and (OR, 0.46; 95% CI, 0.34 to 0.63) respectively. Study [46] found no 
association between TB perception and patient delay. 




A1.1.8. Place of residence  
Seven studies assessed the place of residence as a determinant of patient delay 
[31,37,42,45,46,48,50a]. Only one study [48], found that patient from rural residence being protected 
from the delay (OR, 0.75; 95% CI, 0.61 to 0.92). 
A1.1.9. Marital status  
Studies that assessed marital status for its association with patient delay found the association to be 
not significant [42,45,46,49,50a].  
A1.1.10. Literacy   
Four out of eight studies found significant association between literacy and patient delay 
[42,43,45,48], (OR, 1.97; 95% CI, 1.36 to 2.86), (OR, 3.83; 95% CI, 1.46 to 10.06), (OR, 0.50; 95% 
CI, 0.37 to 0.68) and (OR, 1.69; 95% CI, 1.29 to 2.20) respectively.  
A1.1.11. Smoking    
Four studies assessed smoking as predisposing factor to patient delay [31,46,48,50a]. The association 
was not significant among all the studies. 
A1.1.12. Presence of chronic health problem  
Four studies assessed this factor, in which one study [45] found presence of chronic health problem to 
be significantly associated with patient delay (OR, 1.16; 95% CI, 1.05 to 2.48). Another study [46], 
found the association to be imprecise i.e. wide CI (OR, 3.99; 95% CI, 1.10 to 14.54). One study found 
chronic illnesses to be protective from the delay [50a] (OR, 0.55; 95% CI, 0.33 to 0.94). And the left 
one found no significant association [31]. 
A1.1.13. HIV status    
Surprisingly only one study had looked on HIV to be predisposing factor for patient delay, in which 
the association was not significant [31]. 
A1.1.14. TB related stigma 
Four studies assessed stigma to be a predisposing factor for patient delay in which two studies [42,45] 
found non-significant association. One study [50a] found the TB related stigma to be significantly 
associated with delay (OR, 2.07; 95% CI, 1.05 to 4.08) and the other one found stigma to be 
protective from the delay [48] (OR, 0.74; 95% CI, 0.55 to 0.99). 
A1.1.15. Contact with TB case  




Two studies assessed this factor, while one study [46] found it to be significantly associated with 
patient delay (OR, 1.83; 95% CI, 1.01 to 3.30),  the other one [37]  found it to be protective from 
delay (OR, 0.50; 95% CI, 0.26 to 0.96).  
A1.1.16. Self-medication 
Two studies assessed this factor, while one study [47] found no significant association with patient 
delay, the other one [50a] found it to be significantly associated with delay (OR, 2.53; 95% CI, 1.20 to 
5.62). 
 
A1.2. Enabling factors for patient delay 
 
The only enabling factors assessed among the included studies were travel time, expenses of care and 
place at first consultation. 
A1.2.1 Provider at first consultation 
Consulting health care provider vs. other provider (traditional healer, drugs seller and other) was 
protective from patient delay (OR, 0.77; 95% CI, 0.70 to 0.85). Five studies contributed to summary 
odd ratio [42,45,47,37,50a]. Heterogeneity was insignificant (P= 0.30; I² = 17%) 
 
Figure C9; Forest plot, place at first consultation vs. patient delay. 
A1.2.2 Travel time  
Four studies assessed travel time/ distance to health facility for its association with patient delay found 
the association to be not significant [42,45,48,50a]. 
A1.2.3 Expenses   
Only one study [42] assessed this factor in which the association was significant with patient delay 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.3.3 Health system delay 
 
From the 20 included studies, 15 studies measured the length of health system delay. All the studies 
used the health facility‘s record of first consultation as the starting point and all except two used start 
of treatment as the endpoint (two used diagnosis). The majority of the studies measured delay as a 
dichotomous variable based on a cut-off point, usually the median. The shortest mean duration of 
health system delay (5 days) was reported in Iraq by [50a], whereas, the longest mean duration 
(129.25 days) was reported in Iran by [36].  
 
4.3.4 Analysis of health system delay by subgroup 
B.1 Factors associated with health system delay 
 
Out of 15 studies that measure the length of health system delay, only six studies analysed at least one 
factor associated with this period [41,37,38,47,49,50a]. The studies frequently assessed the enabling 
factors such as type of facility and type of providers at first visit, number of visits and number of 
providers consulted before reaching TB diagnosis, expenses and travel time. These factors are related 
to the aspect of health system delay in which patient return for diagnosis and treatment is required. 
They also may indicate health provider‘s perceptions of patients that may cause them to be less/more 
likely to test for TB. The only predisposing factors assessed in those six studies were the age, sex and 
patient income. 
B1.1 Predisposing factors to health system delay 
B1.1.1 Age  
Three studies assessed Older age as predisposing factor for health system delay in which no 
significant association was reported in [49,37]. The third study from Iran [50b] found the older age to 
be weakly significantly associated with delay (OR, 1.001; 95% CI, 1.003 to 1.007).  
 
B1.1.2. Gender  
 
Female gender was significantly associated with health system delay (OR, 2.12; 95% CI, 1.24 to 3.60) 
in three studies that contributed to the summary odd ratio [49,37,47]. Heterogeneity was significant (P 
= 0.14; I² = 49%). 





Figure C10; Forest plot, Gender vs. health system delay. 
B1.1.3 patient’s income 
 
The two studies that assessed patient‘s income for its association with health system delay found the 
association to be not significant [37,47]. 
  
B1.2. Enabling factors to health system delay  
B1.2.1 Expenses 
Only one study looked for the association between expenses and health system delay in which, high 
cost of medical services was found to be weakly significantly associated with health system delay 
(OR, 1.01; 95% CI, 1.00 to 1.10) per pound) in Egypt [50c]. 
B1.2.2 Type of health facility at first visit  
Three studies assessed whether public or private facility as sources for health system delay 
[49,45,50b]. These studies found the private facilities to be significantly associated with health system 
delay (OR, 1.41; 95% CI, 1.06 to 1.88). Heterogeneity was insignificant (P = 0.53; I² = 0%). 
 
Figure C11; Forest plot, type of health facility at 1st visit vs. health system delay. 
B1.2.3 Type of provider at first visit  




Three studies had looked on the association between type of provider at first visit and health system 
delay [47,37,50c]. However, there were not combinable to calculate an effect size. Visiting non health 
care provider was significantly associated with health system delay (OR, 1.89; 95% CI, 1.20 to 2.90) 
in Egypt [50c]. Güneylioglu et al. 2004 [37] looked specifically on the specialization of the provider 
.i.e. chest specialist or general practitioner. He found that, patients referred by a chest specialist had a 
significantly shorter referral interval than those referred by the other physicians. No significant 
association reported by Rahim et al.2004 [47]. 
B1.2.4 Number of visit before diagnosis  
Two studies looked on this factor as a source of delay [49,47]. However, there were not combinable to 
calculate an effect size. Akrim et al. 2014 found the association between more than three visit to HCP 
and health system delay to be imprecise (OR, 4.66; 95% CI, 2.09 to 10.62). While [47] found the 
number of visit to the same provider was significantly strongly associated with health system delay 
(r= 0.674). 
B1.2.5. Number of providers encountered before diagnosis   
More than one provider encountered before diagnosis was significantly associated with health system 
delay (r= 0.605; p<0.01) (OR, 6.87; 95% CI, 4.80 to 9.90) in Sudan [47]  and Iran [50b] respectively. 
While not significant in Morocco [49], 
B1.2.6 Type of investigation requested at first visit  
Taking sputum smear at 1st attendance at a health facility was significantly inversely associated with 
health system delay (OR, 0.25; 95% CI, 0.22 to 0.28) while obtaining a negative smear result for acid-
fast bacilli was significantly associated with health system delay (OR, 3.3; 95%CI, 2.94 to 3.66) in 
Iran [50b]. On the other hand, not performing TB investigation specifically chest x ray and sputum 
smear on the first visit was significantly associated with health system delay in Sudan [47]. 
Furthermore, [47] found that sputum smear was performed for only 48.8% of the patients who 
consulted private providers. Same way, Chest X-ray and sputum smear examinations were 
underutilized by physicians in Turkey [37].  
 
B1.2.7 Provider suspicion index   
 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.3.5 Contribution of patient and health system delay in total delay 
 
Out of our 20 included studies, fourteen studies assessed both patient and health system delays. These 
studies also took into account the total delay, which measures the patient‘s and the system‘s contribution 
to delay from the time of first symptoms to the start of treatment. Out of these 14 studies, nine studies 
[35,38,41,42,45,47,49,50a,50d] found the delay to be attributed to the patients. Whereas in the other five 
studies [32,33,40,50b,50c] the delay was mainly due to the health system. This can be translated into that; 
six countries in the region (Yemen, Morocco, Syria, Sudan, Iraq and Somalia) should mark an 
intervention aim to reduce the patient delay such as increasing the public awareness about TB. While in 
Egypt the efforts should pay to the health system strengthening and building good referral system and 
engaging the private and non-formal health providers in TB control. Turkey and Iran should work on both 
components to reduce the delay.







4.3.6 HETEROGENEITY IN INCLUDED STUDIES 
Patient delay factors 
Heterogeneity was significant for these factors; gender, patient‘s income, and crowding (P <0.1; I² = 
45%), (P <0.00001; I² = 92%) and (P= 0.15; I² = 47%) respectively.  Further investigation revealed that: 
  
 For factor gender, Rumman et al. 2008 was the source of this heterogeneity.  The participants in 
[48] were TB suspect rather than confirmed TB cases as in the other studies. Removal of this 
study from the meta-analysis for subgroup rendered the heterogeneity insignificant (H, p=0.47; I2 
= 0%).  
 
 For the Patient’s income, the measurement of patient income used in Mohamed et al. 2013 and 
Guneylioglu et al. 2004 was different from the rest of the studies [37,46].  Removal of these 
studies from the meta-analysis, rendered the heterogeneity insignificant (H, p=0.30; I2 = 18%).  
 
 For the Crowding, the cut-off point for crowding index was higher in Maamari 2008 than in the 
other studies [45]. Removal of this study from the meta-analysis, rendered the heterogeneity 
insignificant (H, p=0.84; I2 = 0%). 
 
 
Health system factors  
Gender 
Heterogeneity was significant (P = 0.14; I² = 49%):  further investigation revealed that the source of 
heterogeneity was Guneylioglu et al 2004 [37]. Removal of this study from the meta-analysis, rendered 
the heterogeneity insignificant (H, p=1.00; I2 = 0%). 







4.3.8 GRADING THE QUALITY OF EVIDENCE 
We used GRADE approach to assess the quality of evidence pooled in meta-analysis that are related to 
each significant factors associated with patient and/or health system delay using GRADEpro software. 
The meta-analysis included 12 observational studies. These studies were appraised for limitations to 
validity wherein it was found that measurement of the outcome was dependant on patient‘ self-report, so 
this created a possibility of bias (recall bias).  The effects of the exposure in the 12 studies were assessed 
for similarity and it was found that there was consistency and that a meta-analysis was appropriate. 
Driven by concern for the shortcomings of the observational studies and plausibility of bias as well as the 
small size estimates except for the relation between female gender and health system delay (other 
estimates are not with rule of >2 or <0.5) and implications for the repeatability and generalizability of the 
estimates application of the GRADE system has produced a low quality grading for the evidence in this 
review. In view of the low quality of evidence the implications of this grading are that further research is 
very likely to have an important impact on our confidence in the estimate of effect and is likely to change 
the strength of the estimate. 
 
Table C8: Summary of finding table on the quality of evidence  
Population: TB patients or suspected TB patients. 
Settings: MENA 
Patient delay 
Outcomes Impacts No of 
Participants 
(studies) 
Quality of the 
evidence 
(GRADE) 
Gender    Female gender had more patient delay (OR, 1.24; 95% 






Age  Older age had more patient delay (OR, 1.42; 95% CI, 











Patient’ income Low income had more patient delay (OR, 1.95; 95% CI, 






Crowding index Low crowding index is protective from patient delay 












Provider at 1st 
consultation  
Consulting health care provider vs. other provider 
(traditional healer, drugs seller and other) was 







Health system delay 
Gender  Female gender had twice the risk of health system delay 





Facility at 1st 
visit 
Private facilities had more health system delay (OR, 





**We rated down the quality of the evidence by two points, because of shortcomings of the observational studies 
and plausibility of bias in included studies. 
GRADE Working Group grades of evidence 
High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect 
and may change the estimate. 
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect 
and is likely to change the estimate. 
Very low quality: We are very uncertain about the estimate. 








5.1 Summary of main results 
From a comprehensive literature search we identified 303 records of which 20 full-text articles met our 
inclusion criteria of the review. Of the twenty included studies, sixteen assessed both sources of delay, 4 -
studies assessed patient delay only and 2 studies assessed total delay without demarcation between patient 
and health system delay. Seventeen studies measured the length of patient delay in which only 10 studies 
analysed the factors attributed to this period [31,37,42,43,45-50a]. Out of 15 studies that measure the 
length of health system delay, only six studies analysed at least one factor associated with this period 
[37,38,41,47,49,50a]. In all the studies standard definition for patient delay was consistent, but not for 
health system delay. Female gender was the only factor that are associated with both patient and health 
system delay.  
For the patient delay; the predisposing factors that were significantly associated with patient delay are; 
older age, female gender, unemployment, low patient income, and crowding. Inadequate TB knowledge 
was found to be significantly associated with patient delay in two studies [42,50a]. High TB perception 
was protective from delay in two studies [43, 48] and predisposes to delay in one study [46].  Literacy 
was found to be significantly associated with patient delay in four studies. Rural residence found to be 
significantly associated with patient delay in one study [48], and presence of chronic health problem in 
two studies [45,46]. TB-related stigma was protective from patient delay in one study [48] and predispose 
to patient delay in another study [52]. Contact with TB case was found it to be significantly associated 
with patient delay in one study [46] and to be protective from delay in another study [37]. Self-medication 
founded to be  significantly associated with patient delay in one study [50a] and not significantly 
associated in another study [47]. Marital status, smoking, and HIV were not associated with patient delay 
in all studies that looked on these factors. Provider at first consultation was the only enabling factor that 
we had sufficient information to calculate summary odd ratio in which consulting with non-health care 
provider was associated with longer patient period. The high cost of medical services was significantly 
associated with patient delay in one study [42]. Travel time was not associated with patient delay in all 
the studies that looked on it. 
 






Older age, female gender and patient income were the only predisposing factors that assessed for health 
system delay in our included studies. Older age was weakly associated with health system delay in one 
study and patient income was not associated with health system delay in all the studies that looked on it. 
The enabling factors for health system delay was high cost of medical services in one study [50a], private 
facilities at first visit in two studies [49,50b], non-health care provider i.e. traditional healer and 
community or village healer at first visit in one study [50c], more than three visit to health provider in one 
study [49] and repeated visit to same provider in one study [47], not performing sputum examination on 
the first visit in [50/Iran], obtaining negative result on sputum microscopy in [50b], underutilization of 
chest x-ray and smear microscopy in Sudan [47] and Turkey [37] and finally low suspicion index in three 
studies from Turkey [37,38,41]. 
Table C8: summary of findings for patient delay factors  
Predisposing factors  Studies assessed this factor Summary odd ratio 
Female gender  [31,37,42,43,45-50a] (OR, 1.24; 95% CI, 1.02 to 1.50)  
Older age  [31,37,42,45-50a] (OR, 1.42; 95% CI, 1.19 to 1.69),  
unemployment [42,45,46,48,50a] (OR, 0.83; 95% CI, 0.72 to 0.95) 
Low patient income [37,42,45-48,50a] (OR, 1.95; 95% CI, 1.07 to 3.55)  
High crowding index [42,45,50a] (OR, 0.75; 95% CI, 0.57 to 0.99) 
Residence  [31,37,42,45,46,48,50a] NS 
Marital status [42,45,46,49,50a] NS 
TB knowledge [42,45,47-50a] NS 
TB perception [43,46-48]. NS 
TB stigma [31,46,48,50a] NS 
Literacy  [42,43,45,48] NS 
HIV [31] NA 
Smoking [42,45,48,50a] NS 
Chronic illnesses [31,45,46,50a] NS 
Contact with TB case [37,46] NS 
Self-medication [47,50a] NS 
Provider at 1st consultation [42,45,47,37,50a] (OR, 0.77; 95% CI, 0.70 to 0.85) 
Travel time  [42,45,48,50a] NS 
Expenses [42] NA 
NS; not significant, NA; not applicable; OR; odd ratio, CI; confidence interval. 







Table C9: summary of findings for health system delay factors 
Predisposing factors  Studies assessed this factor Summary odd ratio 
Older age  [49,37,50b] NS 
Female gender  [49,37,47] (OR, 2.12; 95% CI, 1.24 to 3.60)  
Low patient income [37,47] NS 
health facility at 1st visit [49,45,50b] (OR, 1.41; 95% CI, 1.06 to 1.88) 
Expenses [50c] NA 
Provider at 1st visit [37,47,50c] NA 
visits before diagnosis [49,47] NA 
providers before diagnosis  [47,49,50b] NS 
investigation requested at 1st visit [37,47,50b] NA 
Provider‘s suspicion index [37,38,41]. NA 
NS; not significant, NA; not applicable; OR; odd ratio, CI; confidence interval. 
 
5.2 LIMITATIONS 
There are some limitations to this review. The included studies were limited by their designs; the included 
cross-sectional studies had poor comparability and were oppressed with numerous confounders. This 
might have introduced some degree of bias to the review. Also cross-sectional studies limited by the 
temporal bias and cannot reach the causality. Some studies had used different start point and end point for 
the definition of health system delay, this limit the comparability of these studies, and make it difficult to 
combine them in the meta-analysis. In the meta-analysis we choose to include those studies that adopted 
the WHO definition that presented under ―operational definition‖ at the beginning of this document.  
Another limitation is the generalizability of our findings, most of the studies recruited patients from 
public health facilities and TB management units (TBMUs) near the center or the capital of the country 
and no recruitment from private health facilities and from the peripheries were done. Hence to obtain 
generalizability, future studies should recruit the patients from private health facilities and patients from 
marginalized and far areas. Also, two articles were translated into English [20,49] which might have led 
to information loss, thus reducing the quality of data extracted. 






5.3 AUTHORS’ CONCLUSIONS AND RECOMMENDATIONS 
 
5.3.1 Implications for Practice 
This review identified numerous factors contributing to patient and health system delay. These factors 
need careful attention from the TB control planners when detailing the future interventions in order to 
reduce the delay and contain the transmission of the disease in the region. The commentary in this thesis 
raises the dilemma, that the region could not find a way to the case detection rate unless the regions paid 
extensive attention to the following points. The review suggest the need of paying more attention to 
health system enabling factors in the region and clearly announces that there are multiple windows for 
opportunities existing to reduce delay. Efforts should be enhanced to increase public awareness and 
promoting health education about TB especially in outreach areas. Maintaining of high suspicion index 
for TB among the health care providers is mandatory; this can be achieved through effective periodic 
training, monitoring and evaluation. In addition, there is desperate need for engaging all type of providers 
(public, private and non-formal providers) in tuberculosis care and control and building good referral 
system. Furthermore, building interventions that understand the gender discrepancies and differences in 
the region is critical for TB control particularly this review found that the female gender have twice the 
chance of both delays. Lastly, this review suggests incorporating more active case-finding interventions 
into current TB control efforts, mainly among the high risk group. 
5.3.2 Implications for Research 
This review revealed several research gaps; first, the majority of our included studies were cross-
sectional. Cross sectional study design are useful in measuring prevalence and identifying associations 
still could not reach the causality [6]. So, other designs such as cohort design studies are needed to 
establish the causality. Secondly, the data on delay of TB among HIV patient is deficient. According to 
UNAIDS the region have fastest growing of HIV epidemic but the data is not available [53]. Hence, more 
research on HIV-related factors that might influence the diagnosis and treatment for TB is needed 
especially to the programmes and interventions planner. Thirdly, the data on health system related factors 
is lacking, out of 15 studies that measure the length of health system delay only six studies assessed few 
factors related to this period. Therefore, we recommend that future studies should assess more health 
system-related factors. Fourthly, as majority of our included studies assessed passive case finding i.e. 
patient wait longer until she/he recognized the severity of her/his symptoms and feel the need to go to the 






health facility: this might create an opportunity for recall bias when measuring the patient delay 
depending on self-reports thus, to overcome this problem more studies through active case finding are 
needed. Also, there is a need for a systematic review of the incidence rates based on which countries in 
the region determining a target 70% detection rate, as DOTS suggested.   
Lastly, our review does not include the qualitative studies, the usefulness of these studies are their 
strength in identifying factors like stigma that are difficult to be measured by the quantitative studies. 
Therefore the need for qualitative studies to assess factors such as stigma and consulting traditional 
healers is warranted. 






5.4 DIFFERENCE BETWEEN PROTOCOL AND REVIEW 
We planned in the protocol to use mean differences to summarize results for continuous outcomes. 
However, all the continuous outcomes such as age, income, number of visit and crowding index were 
already categorized in the primary studies; hence we don‘t find continuous variables to apply mean 
differences to them. 
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Appendix 1: Search strategy: 
Search strategy developed in MEDLINE 
#1 Search (TB or pulmonary tuberculosis or tuberculosis or mycobacterium tuberculosis) 
#2 Search (patient delay or health-seeking delay or care-seeking delay) 
#3 Search (health facility delay or health provider delay or doctor delay or diagnostic delay or 
diagnosis delay or total delay or detection delay or identification delay or treatment delay) 
#4 Search ((Algeria OR Bahrain OR Djibouti OR Egypt OR Iraq OR Jordan OR Kuwait OR 
Lebanon OR Libya OR Jamahiriya OR Mauritania OR Morocco OR Oman OR Palestine 
OR Qatar OR Saudi Arabia OR Somalia OR Sudan OR Syria OR Tunisia OR The United 
Arab Emirates OR Yemen OR Iran OR Islamic Republic OR Israel OR Turkey OR 
Armenia OR Azerbaijan OR Georgia) 
#6 Search (((((TB or pulmonary tuberculosis or tuberculosis or mycobacterium tuberculosis))) 
AND ((health facility delay or health provider delay or doctor delay or diagnostic delay or 
diagnosis delay or total delay or detection delay or identification delay or treatment 
delay))) AND ((patient delay or health-seeking delay or care-seeking delay))) AND 
((Algeria OR Bahrain OR Djibouti OR Egypt OR Iraq OR Jordan OR Kuwait OR 
Lebanon OR Libya OR Jamahiriya OR Mauritania OR Morocco OR Oman OR Palestine 
OR Qatar OR Saudi Arabia OR Somalia OR Sudan OR Syria OR Tunisia OR The United 
Arab Emirates OR Yemen OR Iran OR Islamic Republic OR Israel OR Turkey OR 
Armenia OR Azerbaijan OR Georgia)) 
 






Appendix 2: Data extraction form 
 
Title:  










Name/ID of person extracting 
data 
 
Reference citation  
Study author contact details  
 
Publication type 
(e.g. full report, abstract, letter) 
 
References (of potentially eligible 











(Insert inclusion criteria for each characteristic 
as defined in the Protocol)   
   
MENA country YES                                                     specify………………… 
No                                              
Participants Suspect TB                           
Newly diagnosed                    
 smear positive PTB             
smear negative PTB             
retreatment                               
Other                                     specify………………………             
Sample size  
Study design Quantitative                      
Qualitative                     
INCLUDE                         EXCLUDE  












DO NOT PROCEED IF STUDY EXCLUDED FROM REVIEW 
 
CHARACTERISTICS OF INCLUDED STUDIES 
Methods 
 
 Descriptions as stated in article/report 
 
Location in text or 
source  
(pg&fig/table/other) 
Aim of study 
 
What was the study designed to assess?  
Study Design    Randomised Controlled Trial         
   Non-Randomised Trial                       
   Cohort Study                                     
   Case-control study                          
   Cross-sectional study                       
   Other 
 
Start date   







obtained    
Yes    No      Unclear 
 
Informed consent and 
assent obtained  
 
   
















(from which study 










Health facility   Public TB health facility             
 Public non TB health facility        
private facility                               
Other                                             specify …………… 
 
Distance to health facility  
 
Less than 1 hour                    more than 1 hour   
Not assessed  
 
Lab resources  related to TB 
diagnosis 
 Smear +chest x-ray                   
 point care                             
centralized lab                      
gene xpert                             
 
Setting 
(including location and social 
context) 




Inclusion criteria   
Exclusion criteria   







 Description as stated in paper 
 
Location in text 
Number 
(Total no. Enrolled) 
  
Age Age range, mean (standard deviation)  
Gender Number; %  female                                     male  
Other health problems   
Notes:   
 
FACTORS ASSESSED FOR ASSOCIATION WITH PATIENT’ DELAY: 
 
  Location in text or 
source  
(pg& /fig/table/other) 











Cut-off point used to 
consider this delay 
  
 No of patients above the 
cut-off point 
No of patients below the cut-off point  
  
 PROPORTIONS  Total  Delayed  Not-delayed  
Place at first 
consultation 






Clinic    
Private doctor     
Public hospital     
TBMU       
Pharmacy     
 other       
Residence 
 
Urban         
 Rural         
Gender who had 
delay 
Female      
Male     
Age who had delay <15 years     
>15 years    
Marital status 
 
Married     
 Unmarried             
HIV status                           Positive      
 Negative      
Unknown             
    
Smoking status  Smoker     
 
Non smoker            
Alcohol consumption  
 
Alcohol drinker      
 Non-alcohol     
drinker       
Presenting symptoms Cough     














Sputum     
Production    
Chest pain    
Fever    
Haemoptysis    
Night sweat    




   
Education No education     
 
 
Primary level     
Secondary level and 
above 
   
Household size <3 persons     
 
 
3-7 persons    
> 7persons    
Patient‘s income  Low     
Middle    
high    
Socioeconomic status Poor     
 
 
Middle    
High    
Employment Employed 














   
TB perceptions/  
Suspicion of having 
Yes     






TB by patient  
 
No       
Travel time to health 
facility 
< 15 min     
  15-60 mins    
 Hour -2 hours    
>2 hours     
How they get to the 
health facility 











Yes      
 No     
Self-medication Yes      
 No    
Stigma reported by 
patient  
Yes      
 No     
Other Specify      
 
 
FACTORS ASSESSED FOR ASSOCIATION WITH HEALTH’ SYSTEM DELAY: 
 
 Present in numbers  Location in text 
or source  
(pg& 
/fig/table/other) 
Time from First 
consultation visit to 
diagnosis (mean±SD) 
  
Cut-off point used to 
consider this delay 
  
 No of patients above the No of patients below the cut-off point  








Number of visits to the 
provider  
  
Number of provider 
consulted before 
diagnosis achieved  
  









Public health facility     
TBMU                    
Other specify     
Type of provider Public providers     
Private providers    
Both private and 
public providers 
   
Other types of 
providers (NGO clinic 
or pharmacist). 
   
Type of provider who 
made the  successful 
diagnosis 
Public providers     
Private providers    
Both private and 
public providers 
   
Other types of 
providers (NGO clinic 
or pharmacist). 
   
Type of referral if the 
diagnosis was not 
successful  
No referral          
Referral to TBMU     
  
Referral to non TBMU 
   
Diagnosis made based 
on  clinical picture 
only  




No     
If yes specify the reasons .e.g shortage of lab equipment or no chest 
x-ray machine 













Type investigation c x 
requested by provider 
No investigation     
Tuberculin skin test     
Sputum microscopy    
Chest x-ray      
Culture    
Gene xpert    
Other     
Place at where these 
investigation 
performed 
Private health facility     
Public health facility    
Both public and 
private  
   










to the  result  
 
 Proportions  Total  Delayed  Not  
Type of diagnosis 
offered by provider 
Tuberculosis      
Non tuberculosis    
Type of treatment 
offered by provider 
TB treatment    
Non TB treatment      
Time from the correct 
diagnosis  to initiation 
of treatment  
 




Stigma related to 
TBMU – BY WHOM? 
 Total  delayed Not-delayed 
YES    
NO     
Other (specify)      
Other Outcomes 
 
Outcome 1:   Patient delay 
 Description as stated in report/paper 
 
Location in text 
(pg&/fig/table) 






What is the name used in 




Duration ( mean+SD or 
median +IQR) 
  
Outcome definition    
Unit of measurement  
Days, weeks or months 
 
  
Method of assessing 
outcome measure 1 
Eg. Duration of symptoms by questionnaire, date of first 
provider visit in the doctor record/ day of result of diagnostic 






Outcome 2:   Health system delay 






What is the name used in 
the study to describe 
health system delay 
 
  
Duration ( mean+SD or 
median +IQR) 
  
Outcome definition    
Unit of measurement  
Days, weeks or months 
 
  
Method of assessing 
outcome measure 2 
Eg. Duration of symptoms by questionnaire, date of first provider 





                                  
Outcome 3:   Total delay 





Duration ( mean+SD or 
median +IQR) 
  
Outcome definition    






Unit of measurement  
Days, weeks or months 
 
  
Method of assessing 
outcome measure 3 
Eg. Duration of symptoms by questionnaire, date of first 






Risk of bias assessment 
 
Hoy et al 2012 criteria for cross-sectional studies modified by Werfalli et al 2014  
 
Was the study's target population a close representation of 
the national population in relation to relevant variables? 
 
 
Yes         No          Unclear  
 
Was the sampling frame a true or close representation of the 
target population? 
 
Yes         No          Unclear  
 
Was some form of random selection used to select the sample, 
OR was a census undertaken? 
 
Yes         No          Unclear  
 
Was the likelihood of nonresponse bias minimal? Yes         No          Unclear  
 
Were data collected directly from the subjects (as opposed to 
a proxy)? 
 
Yes         No          Unclear  
 
Was an acceptable case definition used in the study?  
Yes         No          Unclear  
 
Was the study instrument that measured the parameter of 
interest shown to have validity and reliability? 
 
 
Yes         No          Unclear  
 
Was the same mode of data collection used for all subjects?  
Yes         No          Unclear  
 
Was the length of the shortest prevalence period for the 
parameter of interest appropriate? 
 
Yes         No          Unclear  
 
Were the numerator(s) and denominator(s) for the parameter 
of interest appropriate? 
 
Yes         No          Unclear  
 
Authors’ reported limitations of study’s methods/results   
Yes         No          Unclear  
 






NEWCASTLE - OTTAWA QUALITY ASSESSMENT SCALE 
CASE CONTROL STUDIES 
Note: A study can be awarded a maximum of one star for each numbered item within the Selection and 
Exposure categories. A maximum of two stars can be given for Comparability. 










1) Is the case definition adequate? 
a) Yes, with independent validation 
b) Yes, eg record linkage or based on self-reports 
c) No description 
2) Representativeness of the cases   
a) Consecutive or obviously representative series of cases 





3) Selection of Controls   
a) Community controls  
b) Hospital controls 







4) Definition of Controls   
a) No history of disease (endpoint)  





Comparability   
1) Comparability of cases and controls on the basis of the 
design or analysis 
  
a) Study controls for TB knowledge (Select the most 
important factor.)  
b) Study controls for any additional factor stigma, gender 
(This criteria could be modified to indicate specific Control 
  






for a second important factor.) 
Exposure   
1) Ascertainment of exposure 
a) Secure record (eg surgical records)  
b) structured interview where blind to case/control status  
c) Interview not blinded to case/control status 
d) Written self-report or medical record only 













2) Same method of ascertainment for cases and controls   






3) Non-Response rate   
a) Same rate for both groups  
b) Non respondents described 










 Description as stated in report/paper Location in 
text 
(pg&/fig/table) 









for further study 
information(from whom, 
what and when) 
Correspondence with authors 
 Question to Author: 
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